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ABSTRACT 
White adipose tissue (WAT) fibrosis is now recognized to contribute to 
obesity-associated metabolic dysfunction. In obesity, WAT expands through both 
adipocyte hypertrophy and hyperplasia and regulators that control these 
remodeling events are only partially understood. However these pathways are 
likely interconnected with those that regulate fibrosis, the excessive pericellular 
extracellular matrix (ECM) deposition that occurs in WAT in obesity. Thus it is 
postulated that WAT fibrosis may limit WAT expansion and further contribute to 
metabolic dysfunction. Several studies have indicated that WAT progenitors 
reside within the vascular niche and in other organs these cells respond to 
numerous proinflammatory and profibrotic mediators. Previous studies have 
identified that the secreted ECM protein, aortic carboxypeptidase-like protein 
(ACLP), is expressed in vascular smooth muscle cells and enhances lung 
myofibroblast differentiation. It is also recognized that in vitro, ACLP expression 
decreases with adipogenic differentiation however its role in this process is 
unknown. The goal of this research was to test the hypothesis that ACLP 
stimulates the differentiation of WAT progenitors into myofibroblasts and 
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represses adipogenesis. Using in vitro adipogenesis assays, ACLP expression 
was found to be rapidly diminished with adipogenesis in mouse and human 
adipose progenitors and was not expressed by differentiated adipocytes. In gain 
of function studies, recombinant ACLP repressed adipogenesis and promoted 
myofibroblast differentiation in both mouse and human adipose progenitors. In 
loss of function studies utilizing chemical inhibitors, ACLP signaling in adipose 
progenitors was dependent on transforming growth factor β receptor activity. 
Analysis of fibrotic WAT revealed ACLP protein expression increased in the 
stromal-vascular fraction (SVF) and co-localized with pericellular ECM 
deposition. Analysis of mRNA expression in fibrotic WAT sub-populations 
revealed that immune cell depleted SVF was the primary source of ACLP. 
Additional studies investigated the cellular origin of WAT myofibroblasts, which 
used transgenic mice with fluorescent reporters for α smooth muscle actin and 
collagen I. Analysis of SVF demonstrated that multiple stromal-vascular cell 
types are capable of differentiating into both adipocytes and myofibroblasts. 
Taken together, these studies identified ACLP as a stromal derived mediator of 
adipose tissue progenitor differentiation and the accumulation of ACLP may limit 
adipocyte expansion in fibrotic WAT.  
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CHAPTER I – INTRODUCTION 
Obesity 
Obesity is a major health epidemic, where for instance in the United 
States over one-third of adults are considered obese (1) resulting in a medical 
expenditure of >$146 billion (2). Obesity is a complex systemic disease (3) often 
caused by nutrient excess resulting in the expansion or increase in white adipose 
tissue (WAT) mass (4). Obesity often results in metabolic dysfunction and is 
associated with increased rates of numerous comorbidities, including type 2 
diabetes (5, 6), cardiovascular disease (7), liver pathologies (8) and increased 
rates of cancer (9, 10). Interestingly, not all obese individuals develop metabolic 
dysfunction (11, 12). Obesity induced WAT expansion requires multiple cell types 
and signaling pathways to ensure proper expansion and tissue remodeling (13). 
WAT remodeling, defined as qualitative and quantitative reorganization of cells 
and structures that occur with nutritional stress, is a coordinated and complex 
physiological response (13, 14). WAT remodeling is the collective response of 
numerous cellular responses and signaling pathways, resulting in inflammation 
(15), angiogenesis, (16) or deposition and remodeling of the extracellular matrix 
(ECM) (17). Certainly WAT remodeling is not limited to these processes, 
however these represent important WAT remodeling events. Insufficient WAT 
remodeling is suggested to be a major link between obesity and development 
  2 
and progression of metabolic dysfunction (18). Understanding WAT remodeling 
is imperative to understand the link of metabolic dysfunction and obesity. 
White adipose tissue remodeling 
WAT is a dynamic endocrine organ which is a primary storage site of 
calories in the form of triglycerides (19-21). During periods of nutrient excess, 
WAT expansion occurs via two processes related to adipocyte expansion, 
hypertrophy and hyperplasia. Hypertrophy is the increase in size of individual 
adipocytes (22). For example, in rodents fed a high fat diet (HFD) for 1 week, 
adipocytes increase in size and undergo a four-fold increase in lipid storage 
capacity (23). Hyperplasia is the increase in the total number of adipocytes via 
differentiation of adipose progenitors (24-28). Adipocyte hypertrophy and 
hyperplasia contribute to the plasticity of WAT, which facilitates metabolic 
homeostasis during times of nutrient excess or deficit. In order for efficient WAT 
expansion to occur, numerous interrelated remodeling processes are activated in 
response to nutrient excess (13). It has been proposed that the rate-limiting step 
for WAT expansion and remodeling is angiogenesis (16). Angiogenesis is the 
formation of new vasculature sprouting from existing vasculature (29). As WAT 
expands, new and larger adipocytes surpass the oxygen diffusional limit resulting 
in hypoxia (30, 31). Hypoxia results in expression and secretion of angiogenic 
growth factors that initiate angiogenesis (29-31). Importantly the vasculature 
delivers oxygen, growth factors, nutrients, hormones and a means to dispose of 
metabolic waste (32). 
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 White adipose tissue progenitors 
The vasculature contributes to adipocyte hyperplasia as it can serve as a 
conduit and source of adipose progenitors (33). For instance, circulating stem 
cells derived from the bone-marrow, can enter the WAT through the vasculature 
and differentiate into adipocytes (33). The vasculature is also a source of adipose 
progenitors as numerous cell types are demonstrated to contribute to adipocyte 
hyperplasia (24-28, 34). Reports have demonstrated adipocytes can originate 
from smooth muscle cell origins (27) and endothelial cells (34). Of note, lineage 
tracing studies using alternative smooth muscle and endothelial cell markers 
(SM22 and Tie2, respectively), to those reported have demonstrated smooth 
muscle cells and endothelial cells may not contribute to adipocyte differentiation 
in vivo (24, 35). Adipocytes can also originate from perivascular cells, cells that 
surround the vasculature (25, 26, 28). Adipose progenitors make up a portion of 
the stromal-vascular fraction (SVF), or cells that are non-buoyant following 
collagenase digestion (36). While multiple adipose progenitors exist within the 
SVF, their relative contribution to WAT remodeling hyperplasia or relation to one 
another remains unclear. Adipose progenitors differentiate into adipocytes 
through a complex process defined as adipogenesis. 
Adipogenesis 
Adipogenesis is a complex process of how a cell differentiates into an 
adipocyte (37, 38). Adipogenesis is controlled by epigenetic and transcriptional 
circuits resulting in the activation and expression of mature adipocyte genes, 
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such as fatty acid binding protein-4 (FABP4), perilipin and adiponectin (39, 40). 
Central transcription factors that regulate this process include peroxisome 
proliferator-activated receptor (PPAR)-γ and CCAAT-enhancer-binding protein 
(C/EBP)-α (41, 42). PPARγ and C/EBPα activation is regulated by a 
transcriptional cascade of members in the C/EBP family (43, 44). C/EBPβ and 
C/EBPδ activation results in activation C/EBPα and PPARy and is permissive to 
adipogenesis (45-47). In contrast, C/EBPγ and CCAAT-enhancer-binding protein 
homologous protein (CHOP) repress C/EBPβ and C/EBPδ, thereby repressing 
adipogenesis (48). Additionally, C/EBPβ exists as two isoforms, where the full 
length isoform (liver activator protein) enables adipogenesis and the truncated 
isoform (liver inhibitory protein) acts as a dominant negative regulator of C/EBPβ 
activity (49, 50). There are two PPARγ isoforms, both of which are similarly 
capable of enhancing adipogenesis (51). PPARγ-1 is highly expressed by 
adipocytes but can be expressed in other cells, including adipose progenitors 
and macrophages (52, 53). PPARγ-2 is adipocyte specific and expression 
increases with adipogenesis (52, 54). Hours following in vitro adipogenic 
induction, histone marks associated with active transcription appear on upstream 
elements of the PPARγ gene (47, 55-57). The now exposed upstream elements 
allow for alternate promoter usage thereby permitting expression of PPARγ-2 via 
C/EBP-mediated activity (55, 58). 
Adipose progenitors can be efficiently differentiated in vitro by growing 
cells until confluent and then treating with a drug cocktail. Adipogenic 
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differentiation is controlled in vitro by administration of a glucocorticoid receptor 
activator (such as dexamethasone), an activator of protein kinase A via a cyclic 
adenosine monophosphate (cAMP) agonist (such as 3-isobutyl-1-methylxanthine 
(IBMX) (45, 59-61) and an activator of insulin-receptor substrate and insulin 
growth factor receptor-1 (such as insulin) (62, 63). Individually these drugs can 
activate different components of the transcriptional cascade. Additional pro-
adipogenic mediators which activate PPARγ, such as thiazolidinediones (64-66) 
and indomethacin (67), can be utilized to further enhance adipogenesis 
especially in primary human adipose progenitors. Adipogenesis is a complex 
transcriptional cascade that is tightly regulated by numerous extracellular 
mediators. 
TGFβ superfamily 
Adipogenesis is controlled by numerous mediators and signaling 
pathways. For instance, transforming growth factor (TGF)-β superfamily ligands 
are secreted growth factors that are crucial for multiple cell lineage choices, 
including adipogenesis (68). Bone morphogenetic proteins (BMP), namely BMP-
2 and BMP-4, are pro-adipogenic (69, 70). BMPs activate downstream mediators 
Smad1/5/9 through enhancing PPARγ transcriptional activity (70-72). In contrast 
TGFβ, namely TGFβ1, are anti-adipogenic (73, 74). TGFβ activates downstream 
mediators Smad2/3, which directly interact with and inhibit C/EBPβ activity (73). 
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Extracellular matrix 
Cell-cell and cell-ECM interactions also regulate adipogenesis. 
Compositional and structural properties of the ECM are sensed by cells which is 
converted to intracellular signaling pathways, termed mechanotransduction (75). 
For instance, adipogenesis is enhanced when adipose progenitors are cultured 
on soft surfaces (76). Additionally, mouse adipose progenitors undergo 
enhanced adipogenesis when embedded in low concentration collagen gels (with 
lower matrix rigidity) compared to high concentration collagen gels (77).  
The composition of the ECM also alters adipose progenitor commitment. 
For instance, adipose progenitors cultured on a fibronectin-rich matrix undergo 
reduced adipogenesis (78). Adipose progenitors undergo enhanced 
adipogenesis when cultured on a basement membrane (79). Cell-cell interactions 
also contribute to adipogenic differentiation by regulating cell shape (80). For 
instance, culturing mesenchymal stem cells in a round configuration compared to 
a spread configuration, achieved with confluence, directs them towards an 
adipocyte lineage (81). Efficient in vitro adipogenesis often requires cell-cell 
contact in numerous adipose progenitor cell lines (82, 83). A major intracellular 
signaling pathway implicated with mechanotransduction involves Rho associated 
kinase (ROCK). When adipose progenitors in vitro are spread flat, ROCK activity 
is increased and the cells do not undergo adipogenesis (80, 84) which can be 
reversed through pharmacologic inactivation of ROCK activity (85). ROCK 
activation results in nuclear translocation of myocardin-related transcription 
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factor-A (MRTFA) and activation of serum response factor (SRF) (86). MRTFA-
SRF represses adipogenesis through down-regulation of PPARγ mRNA and the 
inverse is also true (87, 88). 
Regulators of white adipose tissue remodeling 
In order for efficient WAT expansion to occur, numerous interrelated 
remodeling processes are activated in response to nutrient excess. 
Hypoxia 
Adipocyte hypertrophy results in localized regions of hypoxia within WAT 
as adipocytes surpass the diffusional limit of oxygen (31, 89). Hypoxia in 
adipocytes is hypothesized to be a major initiator of WAT remodeling (14, 18, 31, 
90). For instance, adipocyte hypoxia can be observed as early as three days 
following HFD (91). Hypoxia results in inhibition of degradation, via prolyl 
hydroxylation, of a master transcriptional regulator of hypoxia, hypoxia inducible 
factor (HIF)-1α (92). Active HIF-1α activates numerous genes related to 
remodeling events, including angiogenesis, inflammation and ECM remodeling 
(93, 94). 
Inflammation 
As part of WAT expansion, there is an increase in adipocyte cell turnover 
resulting in cell death and release of lipids (17, 95). For instance in the 
epididymal WAT (eWAT), adipocyte cell death increases from less than 1% to 
16% over the course of a 12 week HFD compared to chow diet (17). Immune 
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cells, including macrophages and mast cells, infiltrate and accumulate in the 
WAT and likely scavenge lipids and cellular debris (96, 97). Macrophage activity 
mitigates lipotoxicity and is required for further WAT expansion (15). 
Histologically, this expansion and infiltration of immune cells is observed as a 
‘crown like structure,’ (CLS), a structure of immune cells surrounding a dead 
adipocyte (17). This immune infiltration also leads to a large release of 
inflammatory cytokines including those that enhance ECM synthesis, such as 
TGFβ and platelet derived growth factor (PDGF) (95, 98, 99). 
Extracellular Matrix 
Cells within the WAT are embedded in a network of ECM (77, 100). As 
part of WAT remodeling, the WAT ECM undergoes quantitative and qualitative 
changes through balancing degradation and synthesis of the ECM. Histological 
analysis has demonstrated the structural and signaling proteins of the WAT ECM 
are composed of fibronectin and collagens, namely collagen I, III and collagen VI 
(14, 101, 102). Collagen VI is particularly important to WAT remodeling and its 
expression is increased with obesity (103-105). Collagen VI is the highest 
expressed collagen in differentiated adipocytes (106, 107). Additionally, during 
adipogenesis collagen VI undergoes extensive remodeling, from diffuse thin 
fibers to an extensive fibrillar network (106, 107). Collagen VI-null obese mice 
have an improved metabolic and inflammatory profile compared to obese wild 
type mice (103). Interestingly, collagen VI-null mice exhibited larger adipocytes 
compared to wild type, suggesting that collagen VI imparts a structural limitation 
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on adipocyte hypertrophy (103). ECM degradation is also important for WAT 
remodeling. For example, matrix metalloproteinases (MMP), a family of 
endopeptidases that cleave ECM proteins, are critical regulators of ECM 
degradation (108, 109). MMP14 is particularly important to adipocyte hyperplasia 
as MMP14-null mice exhibit impaired WAT development (77). Interestingly, 
MMP14-null adipose progenitors respond appropriately to adipogenic stimuli 
however they do fail to develop a lipid droplet when cultured in a collagen rich 
environment (77). This suggests that MMP14-null adipose progenitors cells were 
unable to degrade the surrounding ECM to expand in size (77).  
The ECM has numerous functions beyond providing structural integrity. 
The ECM can regulate the availability of growth factors such as TGFβ (110-112). 
Microfibril-associated glycoprotein-1 is an ECM protein that sequesters TGFβ 
within the ECM (112). Mice with inactivated microfibril-associated glycoprotein-1 
develop obesity with increased rates of metabolic dysfunction (112). Furthermore 
MMPs, namely MMP-2 and MMP-9, can release and activate TGFβ from an 
inactive ECM bound form (111). Collagen VI has also been demonstrated to 
activate inflammatory signaling pathways. A cleavage product of Col6α3, named 
endotrophin, is up-regulated in obese WAT (104, 113). Endotrophin activates 
inflammatory signaling pathways in the WAT and is associated with obesity and 
increased rates of metabolic dysfunction (113). Secreted proteins acidic in nature 
rich in cysteine (SPARC) is an ECM associated glycoprotein enriched in obese 
WAT and is associated with WAT fibrosis (114). SPARC is demonstrated to 
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inhibit adipogenesis and enhance collagen deposition (114). Furthermore, 
SPARC enhances cell-ECM interactions and disrupts cell-cell interactions, 
resulting in increased cell mobilization (115). 
While ECM related genes rapidly change with increased nutrient intake 
(116), little is currently known about the cellular origin of ECM production in WAT. 
Fibroblastic cells, often termed fibroblasts, are a heterogeneous cell type with 
various origins depending on tissue. Fibroblasts are phenotypically defined as 
the primary producers of ECM upon activation (117, 118). Activation is typically 
from a tissue injury stimulus, such as hypoxic adipocytes and inflammation in the 
case of WAT (15, 31, 119, 120). Adipose progenitors can be considered 
fibroblastic cells as studies have demonstrated they secrete and alter their ECM 
during in vitro adipogenesis (107, 121). In vivo studies have identified PDGFRα+ 
adipose progenitors as significant producers of the ECM (122, 123). A handful of 
studies have suggested that adipocytes also contribute to ECM production (103, 
104, 124, 125), however the relative contribution of different cell types in adipose 
tissue to ECM production is unknown. 
Coordination of hypoxia (31), inflammation (15) and ECM remodeling (17) 
is demonstrated to be vital for acute healthy WAT remodeling (18). During times 
of chronic nutrient excess however, these components can become constitutively 
activated or deregulated and each are causatively linked to obesity with 
metabolic dysfunction. 
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White adipose tissue fibrosis 
One such complication that can occur during WAT expansion is fibrosis 
(17, 31, 113, 122, 126). Tissue fibrosis is defined as abnormal accumulation of 
ECM components, resulting from impaired degradation and excessive deposition 
of fibrillar components (127). Fibrosis is often a terminal complication of chronic 
inflammatory pathologies affecting the function of numerous tissues, including 
the skin (128), liver (129), lung (130) and kidney (131). The WAT also can 
undergo fibrosis, which is considered a marker of obesity with metabolic 
dysfunction (102), including type 2 diabetes (113). For instance, pericellular ECM 
deposition is positively correlated with insulin resistance in obese patients (113). 
Total ECM accumulation is used as a measure for fibrosis progression in many 
organs, WAT fibrosis is often defined as ECM accumulation pericellular to 
adipocytes (17, 102, 113, 122, 132). This distinction in ECM accumulation is 
important, as others have described increased WAT ECM accumulation 
correlates with improved metabolic profile (133), however this ECM accumulation 
was not pericellular (134). WAT fibrosis is emerging as a major contributor to 
metabolic dysfunction, however little is known about the cellular origins and 
mediators that contribute to WAT fibrosis. 
Myofibroblast function 
While multiple cells are implicated in the progression of fibrosis, the 
myofibroblast is the primary cell type responsible for ECM deposition and 
remodeling (135). Characteristics and origins of myofibroblasts can vary widely 
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depending on the tissue, however myofibroblasts are defined by a common 
phenotype of a contractile activated fibroblastic cell (136, 137). Under non-
pathological conditions, myofibroblasts become activated following an injury to 
the tissue, deposit and remodel ECM at the injury site and then undergo 
apoptosis following wound contraction (138, 139). When the wound is unable to 
resolve, such as during pathologies associated with chronic inflammation, 
myofibroblast activation persists (127).  
The contractile phenotype of myofibroblasts is due to rearrangement of 
the actin cytoskeleton into stress fibers (140-142). These stress fibers terminate 
at a trans-membrane protein complex at the cell surface, which is linked to the 
ECM (143, 144). This trans-membrane protein complex includes integrins and 
focal adhesion kinase (FAK) (144). Through this cell-ECM interface, stress fibers 
generate force against the ECM thereby enabling ECM remodeling and 
contraction (145, 146). While the composition of stress fibers is of various actin 
isoforms, myofibroblasts are often described as containing stress fibers 
composed of α-smooth muscle actin (αSMA) (147, 148).  
In addition to the contractile phenotype, myofibroblasts also synthesize 
and secrete ECM molecules (102, 142, 149, 150). For instance, isolated SVF 
cells from obese individuals expressed higher mRNA of fibronectin and collagen I 
(120). Together, this myofibroblast phenotype allows the cells to remodel the 
ECM as well as synthesize and secrete new ECM, thereby resulting in ECM 
accumulation and ultimately fibrosis. 
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Myofibroblast origins 
Lineage tracing studies have identified that myofibroblasts can originate 
from fibroblastic cells in various tissues, such as resident fibroblasts (151, 152), 
progenitor cells (153) and circulating bone-marrow derived fibrocytes (154). 
Myofibroblasts can also originate from non-fibroblastic cells, such as epithelial 
cells (155-157), endothelial cells (158), smooth muscle cells (159) and pericytes 
(160). The relative contribution of each cellular origin to the myofibroblast 
population widely varies depending on tissue and pathology (136). In WAT little is 
understood about the origins of myofibroblast. Adipocytes have been 
hypothesized to dedifferentiate into myofibroblasts (124). In a model of skin 
sclerosis, myofibroblasts were demonstrated to originate from both adiponectin 
expressing adipose progenitors and less so from dedifferentiated adipocytes in 
the subcutaneous white adipose depot (sWAT) (124). Adipose progenitors also 
contribute to myofibroblast expansion. In vitro studies have demonstrated that 
adipocyte progenitors can undergo myofibroblast differentiation when activated 
by inflammatory macrophages (119, 120). In vivo lineage studies have supported 
that adipose progenitors can contribute to myofibroblast expansion (122). There 
are numerous similarities between myofibroblast progenitors observed in non-
WAT fibrosis with WAT adipose progenitors. For instance, lineage studies have 
identified Gli1+ perivascular fibroblastic progenitor populations from kidney, liver, 
lung, heart, bone marrow and skeletal muscle contribute to myofibroblast 
expansion in vivo during various fibroses (153). It is generally accepted that 
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adipose progenitors are perivascular fibroblastic cells (24-28), so it is likely that 
these cells also can contribute to myofibroblast expansion with WAT fibrosis. 
Recently, lineage tracing studies have demonstrated that platelet derived growth 
factor-α receptor (PDGFR)α+ perivascular adipose progenitors (25) contribute to 
myofibroblast expansion following obesity induced fibrosis (122). 
Myofibroblast mediators and signaling pathways 
While myofibroblasts can originate from a wide variety of cell types, 
mediators and signaling pathways involved in myofibroblast differentiation share 
numerous commonalities regardless of myofibroblast origin. Chronic 
inflammation is causatively linked to tissue fibrosis and is considered a primary 
driver of WAT fibrosis via increased secretion of fibrotic mediators, such as TGFβ 
and PDGFs (95, 98, 99). 
Transforming growth factor-β  
TGFβ is considered to be the master regulator of fibrosis across numerous 
tissues (161) and its expression is increased in obese WAT (162). TGFβ is 
secreted as a latent form by numerous cell types, including macrophages (119) 
and myofibroblasts (163), and is often sequestered in the ECM (164). Activation 
of latent-TGFβ is mediated through enzymatic cleavage via MMPs (165) or 
dissociation by thrombospondin (Tsp) (166, 167), integrins (168, 169) and 
through myofibroblast-mediated contraction of the ECM (110). TGFβ exists as 3 
isoforms with similar biologic activity (170), however the TGFβ1 isoform is 
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primarily associated with fibrosis (171, 172). Active TGFβ signals via binding the 
TGFβ receptor (TGFβR)-1, which then dimerizes with TGFβR2 leading to 
activation of the intracellular TGFβR kinase (173, 174). TGFβR kinase activity 
leads to phosphorylation and activation of Smad proteins that modulate 
transcriptional activity of myofibroblast genes, such as αSMA (175, 176) and 
collagens (177-179). Additionally, TGFβ is also anti-adipogenic as active TGFβ 
signaling results in inhibition of pro-adipogenic C/EBP transcriptional activity (73). 
Non-canonical TGFβR activity also is implicated in myofibroblast differentiation. 
Mitogen-activated protein kinase (MAPK) signaling pathways are activated in 
fibrosis. MAPK signaling pathways, such as p38 MAPK (180), c-Jun terminal 
kinase (181), and extracellular-signal regulated kinase (182), can be activated by 
TGFβR and can directly and indirectly influence the TGFβR-Smad signaling axis 
(183). TGFβR mediated MAPK activity can enhance αSMA and ECM expression 
in fibroblasts (184-186). 
Actin cytoskeleton dynamics 
TGFβR activity also can be propagated through changes in the actin 
cytoskeleton that are important for both enhancing myofibroblast differentiation 
and inhibition of adipogenesis (87, 88, 187). TGFβR kinase activity activates 
either small GTPases, such as Cdc42 and RhoA (188), or Rho family guanine 
exchange factors (189) which in turn activate ROCK (190). Active ROCK 
activates Limk2 which deactivates cofilin, a factor that depolymerizes actin, 
thereby shifting the actin cytoskeleton from monomeric globular-actin into 
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polymerized filamentous-actin (191). This change in actin results in release of 
globular-actin binding MRTFA, which enables nuclear translocation and 
activation of SRF (86). MRTFA-SRF transcriptional complex activation promotes 
gene expression of αSMA and ECM related genes and stress fiber formation (86, 
187, 192, 193). 
ECM mechanical properties 
During fibrosis, myofibroblasts continually remodel and deposit ECM 
resulting in increased ECM rigidity (194). Substrate rigidity can be measured by 
applying force across the substrate and measuring the response force, such as 
by atomic force microscopy (195) or by tensile testing (196, 197). ECM rigidity 
can regulate progenitor differentiation (75, 80). The increased ECM rigidity 
activates a series of signaling mechanisms that enhance myofibroblast 
differentiation (110). For instance, increased ECM rigidity results in increased 
activation of ECM bound latent-TGFβ (110). Additionally, αSMA and ECM 
expression is enhanced in fibroblastic cells when cultured on a rigid ECM (198-
200). Through these mechanisms, myofibroblasts increase ECM rigidity, which in 
turn enhances myofibroblast differentiation in non-differentiated cells leading to 
further myofibroblast expansion and further ECM rigidity increases, thereby 
creating a feed forward loop (127, 201, 202).  
Little is known about the ECM rigidity with respect to the WAT. Others 
have measured the tensile strength of WAT from obese patients but no 
correlation was observed with regards to metabolic function (196, 197). Studies 
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have demonstrated that increased mechanotransduction in isolated adipocytes 
embedded in collagen gels results in increased expression of inflammatory 
genes and decreases expression of adipocyte genes (125). 
As adipose progenitors differentiate into adipocytes in vitro, they convert 
from flat fibroblastic cells into rounded adipocytes which is, in part, facilitated by 
the immediate ECM environment (106, 203). Studies have demonstrated that 
human and mouse progenitors grown on soft polyacrylamide gels undergo 
enhanced adipogenesis and have decreased collagen I expression relative to 
progenitors cultured on stiff polyacrylamide gels (77, 204). This change in cell 
shape regulates ROCK activity, where more rigid surfaces result in increased 
cellular tension that increases cytoskeletal actin tension via ROCK activity (205, 
206). 
Integrin – focal adhesion kinase signaling axis 
Cells sense the ECM through a variety of receptors. A central 
mechanotransduction signaling pathway is via integrin-focal adhesion kinase 
(FAK) signaling axis (144). Multiple forms of the cell adhesion receptor, integrins, 
exist and are able to bind to a variety of ECM molecules and modulate 
differentiation pathways (207). Integrins are a part of a trans-membrane protein 
complex that connects the ECM to the actin cytoskeleton (144), which 
consequentially regulates ROCK activity (208). This trans-membrane protein 
complex is composed of numerous proteins, including actins and FAK (144, 209). 
Integrins bind the ECM and through this complex, tension is generated across 
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the actin cytoskeleton resulting in ROCK activation (210). Active integrin-FAK 
signaling is demonstrated to be critical for myofibroblast differentiation and is 
implicated across numerous tissue fibroses (211-214). 
Integrin-FAK activity also regulates adipogenesis (215-217). For instance, 
studies have demonstrated that integrin α5 is decreased via repressed 
expression and increased degradation during adipogenesis, while integrin α6 
expression is increased (215, 216). Active integrin-FAK signaling also promotes 
anti-adipogenic transcriptional cascades (218, 219), including MRTFA-SRF 
(220). However there is also evidence that BMP signaling promotes adipogenic 
commitment phase via FAK activity (221), suggesting a different role for FAK 
activity depending on context during adipogenesis. Studies have also 
demonstrated that pharmacological inhibition of FAK activity enhances 
adipogenesis but can be reversed with enhanced ROCK activity (222). 
Adipose progenitors contribute to both adipocyte and myofibroblast 
differentiation during WAT fibrosis (122). Numerous mediators, including TGFβ 
(73, 119) and mechanical signaling (80, 198), are able to control both adipocyte 
and myofibroblast differentiation pathways. In WAT, TGFβ is primarily 
demonstrated to originate from macrophage infiltration (119) during diet induced 
obesity and can activate numerous signaling pathways such as Smad2/3 (175, 
176) and ROCK (190). TGFβ is not likely a viable therapeutic target, as it is vital 
for numerous critical functions in all tissues and previous attempts have seen 
limited success in abrogating fibrosis (223). Targeting the ECM is relatively 
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unexplored as a potential therapeutic target with regards to WAT fibrosis. In 
addition to being a reservoir of latent TGFβ, the ECM can activate pro-fibrotic 
signaling pathways, including ROCK (208, 210), which can potentially propagate 
fibrosis even in the absence of inflammation (127, 201, 202). A recent study 
utilized a monoclonal antibody against endotrophin, the cleavage product of 
Col6α3, and demonstrated decreased inflammation, fibrosis and improved 
metabolic profile with chronic obesity in mice (113). Given this, identifying ECM 
proteins may provide novel therapeutic targets in fibrosis. 
Aortic carboxypeptidase like protein 
Human aortic carboxypeptidase-like protein (ACLP) is composed of 1158 
amino acids with several domains, including an N-terminal signal sequence, a 
lysine, proline, and glutamic acid rich charged domain containing Tsp repeats, a 
discoidin-like domain, and a catalytically inactive metallocarboxypeptidase 
domain (Fig. 1) (224-226). The gene name for ACLP is adipocyte enhancer 
binding protein-1 (Aebp1). Aebp1 was originally described as a mouse protein 
with protease and transcriptional regulatory activity that shared sequence 
homology with discoidin-like domain proteins (227-230). Aebp1 was reported to 
interact with the promoter region of FABP4 to regulate transcription and that 
adipose progenitors of Aebp1-null mice had reduced adipogenic potential (228, 
229). However subsequent genomic analysis have revealed the original Aebp1 
protein was the result of a cloning artifact and that Aebp1 is actually the C-
terminal region of full length ACLP (225, 231-233).  
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Figure 1 – ACLP Domains 
ACLP is a secreted ECM associated protein containing a lysine, proline, and 
glutamic acid rich charged domain containing Tsp repeats, a discoidin-like 
domain, and a catalytically inactive metallocarboxypeptidase domain. 
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Discoidin-like domain 
The discoidin-like domain of ACLP is similar in structure to the collagen 
binding discoidin domain receptors, which are tyrosine receptor kinases that are 
activated via interactions with fibrillar collagen (231, 234-236). ACLP binds to 
collagen via the discoidin-like domain and this interaction is demonstrated to 
enhance fibroblast-ECM interactions resulting in enhanced collagen gel 
contraction, fibroblast motility and proliferation (226). Connective tissue disorders 
in humans have been recently shown to be caused by null mutations in ACLP 
with alterations in the structure in the connective tissue (237). Furthermore, a 
recent report demonstrated individuals presenting with features reminiscent of 
Ehlers-Danlos Syndrome, including poor wound healing, abnormal scarring, skin 
and joint laxity, have nonsense and small frameshift mutations in or proximal to 
the discoidin-like domain (238). 
Carboxypeptidase domain 
ACLP also contains an enzymatically inactive carboxypeptidase domain at 
the C-terminus, similar to other proteins with an inactive carboxypeptidase such 
as CPX1 and CPX2 (225, 239, 240). Similar to CPX1 and CPX2, ACLP lacks 
critical amino acid residues in the catalytic region to enable carboxypeptidase 
activity (241-243). Currently very little is understood about the function of the 
inactive carboxypeptidase domain. 
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Tissue and cellular origins 
ACLP is a secreted protein expressed predominately by smooth muscle 
cells, fibroblasts and myofibroblasts in collagen rich tissues (244). During 
development ACLP expression is found in the connective tissue, vasculature, 
dermal mesenchymal cells, and in skeletal tissues (243, 244). Genetic ablation of 
ACLP in mice results in a defect in ventral abdominal wall closure resulting in 
gastroschisis and impaired wound healing (245, 246). In adult tissue, ACLP 
expression is predominately localized to the vasculature (including in WAT), lung, 
and skin (243, 244, 247). ACLP expression is increased at sites of wound healing 
and smooth muscle cell proliferation, and is implicated with myofibroblast 
proliferation during fibrosis (226, 246-250). These observations have lead to the 
recent designation that ACLP is a core ECM protein (251). 
Aortic carboxypeptidase-like protein and fibrosis 
As previously stated, ACLP expression is increased in idiopathic 
pulmonary fibrosis and experimentally induced lung fibrosis (226). ACLP-null 
mice were protected against experimental induced fibrosis, with decreased 
number of αSMA expressing myofibroblasts and reduced ECM accumulation 
(226). Interestingly, experimentally induced fibrosis in ACLP-null mice resulted in 
an equivalent inflammatory response compared with wild-type mice, however the 
ACLP-null mice exhibited reductions in subsequent lung fibrosis, suggesting that 
ACLP signaling is downstream of inflammation during fibrosis progression (226). 
Supporting this, later studies demonstrated that ACLP expression is rapidly 
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increased in differentiating fibroblasts, preceding both αSMA and Col1 
expression, and knockdown of ACLP in differentiating fibroblasts dramatically 
reduced the rate of myofibroblast differentiation (250). In fibroblasts, ACLP 
signals via TGFβR signaling, leading to downstream activation of both Smads 
associated with BMP and TGFβ signaling pathways, and TGFβR independent 
signaling (250). TGFβ and ACLP can both activate TGFβR activity, however their 
signaling cascade differs during myofibroblast differentiation. In human lung 
fibroblasts, TGFβ requires downstream activation of MRTFA to enhance collagen 
I expression, while ACLP does not (250). 
Aortic carboxypeptidase-like protein in white adipose tissue 
It was shown that ACLP can be expressed by adipose progenitors and the 
expression decreases early upon adipogenic induction (227, 230, 252, 253). 
Additionally, observations of a transgenic mouse harboring an ACLP promoter 
driving nuclear β-galactosidase demonstrated that perivascular and vascular 
cells express ACLP in WAT (247), which is a major reservoir of adipose 
progenitors (24, 27). These findings suggest that ACLP co-localizes with cells 
others have described as adipose progenitors. Overexpression of ACLP in 
adipose progenitors in vitro inhibited adipogenesis and instead enhanced smooth 
muscle cell differentiation (232). TGFβ treatment of adipose progenitors resulted 
in increased expression of ACLP expression (254). Together, these studies 
suggest that ACLP inversely correlates with adipogenesis, however little is 
known about the mechanism or function of ACLP with respect to WAT fibrosis. 
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Summary 
WAT fibrosis is a consequence of chronic obesity and correlates with 
metabolic dysfunction. WAT fibrosis is the result of persistent myofibroblast 
differentiation, which synthesizes and secretes excessive ECM. In non-WAT, 
myofibroblasts originate from a variety of cells through numerous mediators. 
However in WAT, the origin of myofibroblasts and the mediators that enhance 
myofibroblast differentiation remain poorly understood. Recent studies have 
highlighted that adipose progenitors can give rise to myofibroblasts with diet 
induced obesity (122). ACLP is a secreted ECM associated protein that is 
normally expressed in the vasculature of WAT, a reservoir of adipose 
progenitors. ACLP expression is increased in numerous fibroses and is a 
regulator of myofibroblast differentiation (226, 250). Currently the function of 
ACLP on differentiation of adipose progenitors is unknown. 
Goals of Research  
The goal of this thesis research was to understand the function of 
ACLP in adipose progenitor differentiation and in WAT fibrosis. In order to 
explore the role of ACLP signaling in WAT fibrosis, two hypothesis were 
investigated: 
1. ACLP represses adipogenesis and enhances myofibroblast 
differentiation. Gain of function studies utilizing recombinant ACLP protein and 
adipogenesis assays were performed utilizing a mouse adipose progenitor cell 
line and primary human adipose stromal cells to determine the effect of ACLP 
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signaling on adipogenesis. Additionally, loss of function studies with fibrosis 
signaling inhibitors was performed to delineate the signaling mechanisms of 
ACLP.  
2. ACLP expression increases in WAT fibrosis and is expressed primarily 
by fibroblastic cells. Previous reports suggest that ACLP may be a marker for 
adipose progenitors and its expression is increased with fibrosis. Histological 
analysis with transcript expression analysis from various subpopulations of the 
WAT was performed on WAT following a chronic HFD to understand the 
expression pattern and source of ACLP in WAT fibrosis. 
 
This work presented in this thesis demonstrates that ACLP is a stromal derived 
negative regulator of adipogenesis and enhances myofibroblast differentiation in 
adipose progenitors. These studies also suggest that ACLP may be a therapeutic 
target to ameliorate complications with chronic obesity. 
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CHAPTER II – MATERIALS AND METHODS 
Mice 
SVF and stromal-vascular particulates (SVP) were isolated from C57Bl/6 
male mice harboring an integrated collagen α1 (Col1) promoter driving green-
topaz fluorescent protein (GFPtpz) (Col1-GFPtpz) and an integrated αSMA 
promoter driving mCherry (αSMA-mCherry) (αSMA-mCherry/Col1-GFPtpz) (255). 
SVF were isolated from C57Bl/6 male mice harboring a tamoxifen 
controlled cre recombinase with a conditional knockout of Aebp1 (Cre- 
Aebp1flx/flx). Mice containing an Aebp1 gene harboring a Cre-sensitive LoxP site 
were generated at the University of California Davis mouse biology core and 
were crossed with a mouse harboring a tamoxifen inducible Cre gene (B6.Cg-
Tg)(CAG-Cre/Esr1*)5AmC/j, Jackson Labs) (256). 
 For analysis of diet induced fibrotic eWAT, male mice fed control diet 
(chow) (Jackson, D12450B, 10 kcal% fat) or HFD (Jackson, D12492, 60 kcal% 
fat) starting at 6 weeks of age until 22 weeks were acquired from Jackson 
laboratories and the tissues were provided by Dr. Trinkaus-Randall, Boston 
University School of Medicine.  
The Boston University School of Medicine Institutional Animal Care and 
Use Committee approved all animal experiments. 
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Stromal-vascular fraction, stromal-vascular particulate and adipocyte 
isolation 
Mice aged 8 to 12 weeks were euthanized by CO2 asphyxiation. iWAT and 
eWAT were aseptically removed from the animals. WAT were washed in room 
temperature PBS three times, finely minced, and enzymatically digested for 45 
min at 37°C for 45 minutes. Enzymatic digestion was accomplished by incubating 
minced WAT with 1x dispase (BD Falcon), 1 mg/ml type-1 filtered collagenase 
isolated form Clostridium histolyticum (Worthington, NC9068181), 9 kunitz/ml 
DNase I (Worthington, NC9027449), 1% bovine serum albumin (Fisher 
Reagents, BP1600) diluted in DMEM and 1% penicillin/streptomycin with gentle 
rocking. Following enzymatic digestion, the digestion cocktail was neutralized 
with DMEM containing 10% fetal bovine serum (FBS) (Atlas Biochemicals) and 
1% penicillin/streptomycin, and then total cells were pelleted (400xg, 10 min). 
Following centrifugation, when isolating adipocytes the fatty floating layer was 
carefully removed by pipetting and transferred to a 1.5 ml tube containing 1.02 
mg/ml Ficoll-PBS buffer. Adipocytes were subject to centrifugation (400xg, 10 
min) and then the cell free liquid below the floating adipocyte layer was carefully 
aspirated to not aspirate the isolated adipocytes. For SVF and SVP, the 
supernatant was aspirated and the SVF/SVP containing pellet was retained. The 
pellet was re-suspended and then passed through a 100 micron cell strainer 
(Corning Falcon) and the strainer was washed with DMEM with 10% FBS and 
1% penicillin/streptomycin. Cells that passed through the strainer were 
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considered SVF while cells retained on the strainer were considered SVP. For 
SVF, the cells were pelleted (400xg, 10 min). For SVP, the cell strainer was 
flipped and the washed with DMEM with 10% FBS and 1% penicillin/streptomycin 
to dislodge the SVP. 
Human adipose stromal cells 
De-identified human adipose stromal cells (hASC) were obtained from the 
Boston Nutrition Obesity Research Center Adipocyte Biology Core, with approval 
by the Institutional Review Board of Boston University Medical Center. All 
subjects provided informed consent. 
Recombinant protein 
rACLP was produced and purified as previously described (250). 293 cells 
were stably transfected with a plasmid encoding the BM40 signal peptide-mouse 
ACLP followed by a myc-His tag. Cells were grown in SFM4HEK293 media 
(Hyclone). Media was clarified to remove cells (400xg, 10 min) then supernatant 
was subjected to centrifugation (3000xg, 15 min) and supernatant was collected. 
Supernatant was dialyzed through membranes with 100,000 molecular weight 
cut off (Spectrum, 08-671-41) for 3 consecutive nights each in fresh dialysis 
buffer (300 mM KCl, 47 mM K2HPO4, 3 mM KH2PO4, pH 8.0). Protein was 
purified using a Bio-Scale Mini Profinity IMAC Cartridge (Bio-Rad) in a BioLogic 
Duo Flow chromatography system (Bio-Rad). Protein was washed with wash 
buffer (300 mM KCl, 47 mM K2HPO4, 3 mM KH2PO4, 5 mM imidazole, pH 8.0), 
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then high pH wash buffer (300 mM KCl, 90 mM Na2CO3, 10 mM NaHCO3, pH 
~10.8) and then subsequently eluted with an elution buffer (300 mM KCl, 47 mM 
K2HPO4, 3 mM KH2PO4, 250 mM imidazole, pH 8.0). Eluted protein was 
concentrated with an Amicon centrifugal filter (Millipore) 10,000 molecular weight 
cut off by centrifugation (18,000xg, 18 min). Finally protein was dialyzed against 
PBS containing calcium and magnesium using a 100,000 molecular weight cut 
off Float-A-Lyzer G2 Dialysis (Spectrum). Protein concentration was determined 
using Pierce BCA Protein Assay Kit (Thermo Scientific). 
Cell lines, culture and treatments 
C3H/10T1/2 (10T1/2) (ATCC) fibroblasts and hASC were cultured in 1:1 
Ham’s F12:DMEM supplemented with 10% FBS and 1% penicillin/streptomycin 
and incubated in a 5% CO2 atmosphere at 37°C. 
For adipogenesis studies, experiments were initiated when cells were pre-
confluent (80-90% confluent). For myofibroblast differentiation studies, 
experiments were initiated when cells were pre-confluent (50-70%). 
For rACLP treatments, 10T1/2 fibroblasts, explants, and SVF cells were 
treated with 3.75 µg/ml rACLP (~30 nM). For TGFβ treatments, cells, SVP and 
explants were treated with 200 pM – 1 nM TGFβ (R&D, 240-B-002/CF). For 
TGFβR inhibitor studies, 10T1/2 fibroblasts were treated with 5 µM SB431542 
(Sigma). For ROCK inhibitor studies, 10T1/2 fibroblasts were treated with 1 µM 
Y27632 (Sigma). For FAK inhibitor studies, 10T1/2 fibroblasts were treated with 1 
µM FAK 14 (Tocris Bioscience). For Aebp1 knockout studies, freshly isolated 
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eWAT SVF cells from Cre-Aebp1flx/flx mice were treated with 1 µM 4-OH-
tamoxifen (Sigma) for 3 days with media changes every day to activate cre 
recombinase (256). Following tamoxifen treatments, media was changed to fresh 
media everyday for 3 days to washout tamoxifen. 
For mechanical signaling and FAK studies, cells were plated on 
polyacrylamide gels of varying rigidity (4 kPa and 25 kPa) coated with collagen I 
(Matrigen). 
Stromal-vascular particulate collagen gel culture 
Freshly isolated SVP were embedded in polymerized collagen gels. To 
generate collagen gels, rat tail type I collagen (Sigma, C3867) was diluted to 2 
mg/ml in 1 N sodium hydroxide, 10x PBS diluted to 1x PBS, and the remaining 
volume was brought up with media containing isolated SVP. This collagen gel-
SVP mixture was added to wells, allowed to polymerize for 30 min at 37°C and 
then fresh media was given. 
Adipose tissue explant culture 
iWAT and eWAT were aseptically removed from the animal. WAT were 
washed in room temperature PBS three times and then cut into pieces that were 
approximately 0.5-1 cm cubes. Each cube was cultured in a single well of a 6 
well plate suspended in 2 ml of 1:1 Ham’s F12:DMEM with 10% FBS, 1% 
penicillin/streptomycin and 430 nM insulin (Sigma, I0516) and incubated in a 5% 
CO2 atmosphere at 37°C. Media was changed every 2 days. 
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Adipogenic induction in mouse cells 
Confluent 10T1/2 fibroblasts, SVF cells or SVP were differentiated into 
adipocytes in 1:1 Ham’s F12:DMEM, 10% FBS with 5 μM dexamethasone 
(Sigma, D2915), 500 μM, IBMX (Sigma, I5879), 860 nM insulin (Sigma, I0516), 
and 125 μM indomethacin (Sigma, I7378) (DMII). After 2 days, cells were 
maintained in 10% FBS, 430 nM insulin (Sigma, I0516), for the remainder of the 
study (257, 258). 
To fractionate day +8 10T1/2 cultures, cells were incubated in 0.05% 
trypsin-EDTA for 5 minutes. Cell mixture was re-suspended in 1.02 mg/ml Ficoll-
PBS buffer and then subjected to mild centrifugation (400xg, 10 min). Following 
centrifugation, buoyant cells in Ficoll-PBS buffer were collected with a pipette 
and the collected cells were considered differentiated 10T1/2 adipocytes. For 
non-differentiated 10T1/2 fibroblasts, after isolation of differentiated 10T1/2 
adipocytes, Ficoll-PBS buffer was aspirated and the remaining pellet contained 
non-differentiated 10T1/2 fibroblasts. 
Adipogenic induction in human cells 
Adipocyte differentiation assays of hASC were performed as previously 
described (66) with assistance from Dr. Mi-Jeong Lee. Briefly, hASC were grown 
for 2 days after reaching confluence and then moved to complete differentiation 
media (CDM) containing 500 μM IBMX, 100 nM insulin, 100 nM dexamethasone, 
2 nM triiodothyronine, 10 µg/ml transferrin, 1 µM rosiglitazone, 33 µM biotin and 
17 µM pantothenic acid. hASC was in CDM for 7 days total with a CDM 
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replacement on day 4. Following 7 days of CDM incubation, hASC were 
maintained in serum free media with 10 nM insulin and 10 nM dexamethasone. 
SDS-PAGE and Western blotting 
For 10T1/2 fibroblasts, SVF cells, SVP, adipocytes and hASC, total 
protein lysates were harvested in Western extraction buffer (25 mM Tris pH 7.4, 
50 mM sodium chloride, 0.5% sodium deoxycholate, 2% NP-40 and 0.2% sodium 
dodecyl sulfate) with protease and phosphatase inhibitors (Roche) as described 
(231). Lysates were incubated on ice for 15 min, clarified (12,000xg, 10 min) and 
supernatant was collected. For explants, total protein lysates were harvested by 
suspending explants in Western extraction buffer that was 4x explant volume. 
Lysates were vigorously vortexed for 1 minute every 5-10 minutes for 60 
minutes. Lysates were frozen overnight at -80°C, thawed on ice, pelleted 
(12,000xg, 10 min) and supernatant was collected. Protein concentrations were 
determined with BCA protein assay kit and BSA standards (Thermo Scientific) 
and equal amounts of protein were denatured in lithium dodecyl sulfate loading 
buffer (Life Technologies, NP0007) and reducing agent (Life Technologies, 
NP0009) for 10 min at 70°C. Samples were run on 4-12% NuPage bis-tris protein 
gels (Life Technologies) in 3-(N-morpholino)propanesulfonic acid running buffer 
(Life Technologies, NP0001) at 120 V until the blue dye of the loading buffer 
approached the bottom the gel. Proteins were transferred onto Immobilon-FL 
polyvinylidene difluoride (0.45 µm) membranes (EMD Millipore) in transfer buffer 
(48 mM Tris pH 8.3, 39 mM glycine, 0.037% SDS, 20% methanol) at 23-25 V at 
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4°C overnight. Membranes were probed with antibodies against ACLP (224) 
(1:4000), αSMA (Sigma A2547, 1:4000); collagen α1 (Rockland 600-401-103-
0.1, 1:1000); FABP4 (Cell Signaling 3544S, 1:2000); cyclophilin A (CypA) (EMD 
Millipore 07-313, 1:2000); adiponectin (Thermo Scientific PA1054, 1:2000); 
perilipin (Cell Signaling 9349S, 1:2000); PPARγ (Santa Cruz Biotechnology SC-
7196, 1:1000); CRP2 (259) (1:1500); desmin (Dako M0724, 1:500); SM22 
(Abcam ab14106, 1:1000). Membranes were initially equilibrated with tris 
buffered saline-tween (TBST) (25 mM Tris pH 8.0, 125 mM sodium chloride, 
0.1% Tween 20). Membranes were then blocked in 4% milk-TBST for 1 hour at 
room temperature. Antibodies against collagen α1 and PPARγ were probed with 
primary antibody diluted in blocking buffer at 4°C overnight while all others were 
probed for 2 hours at room temperature. Following primary antibody incubation, 
membranes were washed 3x in TBST, incubated with anti-rabbit or anti-mouse 
(GE Healthcare, 1:4000) horseradish peroxidase conjugated secondary 
antibodies, washed 4x in TBST, incubated with SuperSignal West Dura Extended 
Duration Substrate (Thermo Scientific) and then imaged using a Bio-Rad 
Chemidoc imaging system. For conditioned media samples, equal loading was 
confirmed by membrane staining with Ponceau S solution (Sigma, P7170). 
Protein quantification relative to CypA was measured by densitometry using 
Image Lab software (Bio-Rad). 
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Oil Red-O staining, imaging and quantification 
To measure lipid accumulation, cells were washed 2x with PBS, fixed with 
10% paraformaldehyde (diluted in PBS) for 30 minutes, washed 2x with PBS, 
incubated with Oil Red O (0.5 g Oil Red O (Sigma) per 100 ml of 60% 
isopropanol and 40% water) for 60 minutes and then washed 3x with PBS (260, 
261). Brightfield images were taken with identical exposures on an Olympus IX70 
microscope. Oil Red O was extracted by incubating samples with 100% 
isopropanol for 10 minutes at room temperature. Absorbance of extracted Oil 
Red O was measured at 500 nm using a BioTek Synergy HT plate reader. Empty 
wells stained with Oil Red O as above were used as background and absorbance 
was subtracted from each sample for quantification. 
Quantitative real-time PCR 
RNA was isolated from cells using the GeneJET RNA purification kit 
(Thermo) according to the instructions of the manufacturer. RNA concentration 
was measured utilizing the Take3 Plate on the BioTek Synergy HT system. 
cDNA was generated from 200 ng of mRNA using a Maxima First Strand cDNA 
synthesis kit (Thermo Fisher) according to manufacturer’s instructions. cDNA 
was diluted 1:10 in water prior to analysis. Analysis of gene expression was 
performed using Luminaris Color HiGreen qPCR Master Mix (Thermo Fisher) in 
an ABI Prism 7300 sequence detector using 100 nM intron-spanning primers 
(Table 1). Primers were developed using MGH Primer Bank (262-264) unless 
otherwise cited. Total volume of qPCR reaction was 10 µl. The relative amount of 
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mRNAs was determined through the comparative threshold cycle (ΔΔCT) 
method. PPIA was used as invariant control. 
Magnetic-activated cell sorting 
Magnetic-activated cell sorting (MACS) (Miltenyi Biotec, 130-052-301) was 
performed according to manufacturers instructions on the cells after passing 
through 30 µm cell strainer. Cells were incubated with 10 µl of anti-CD45 
conjugated microbeads per 107 cells for 15 minutes. Cells were washed with 
wash buffer (PBS pH 7.2, 0.5% BSA, 2 mM EDTA). Cells were then passed over 
a MACS MS column in a magnetic field and subsequently washed with 1-2 ml 
wash buffer per 107 cells. Flow-through cells were collected as CD45- SVF. The 
MACS column was then removed from the magnetic field and CD45+ SVF were 
eluted with 2 ml wash buffer and collected. Both SVF underwent centrifugation 
(400xg, 10 min) to pellet cells. Analysis of CD45 purity was performed by 
measuring CD45 mRNA by qPCR on sorted cells. 
Tissue preparation for histology 
eWAT and iWAT was rinsed 3 times in PBS, fixed with methyl Carnoy’s 
fixative (60% methanol, 30% chloroform, 10% glacial acetic acid) for 3 hours at 
4°C and then 70% ethanol overnight at 4°C. Tissues were processed, embedded 
in paraffin and sectioned using standard techniques (244). 
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Picrosirius red staining 
Sections of the eWAT and iWAT (10 µm) were deparaffinized and 
rehydrated by first being incubated at 55°C for 20 minutes, then sequentially 
submerged in xylenes (2x, 5 min each), 100% ethanol (2x, 5 min each), 95% 
ethanol (1 min), 85% ethanol (1 min), 70% ethanol (1 min), 50% ethanol (1 min) 
and lastly distilled water for 1 min. Hydrated sections were stained with 
picrosirius red solution (Electron Microscopy Sciences) for 90 minutes at room 
temperature, rinsed with 0.01 N HCl (2x, 2 min each). Sections were then 
dehydrated by being sequentially submerged in 50% ethanol (30 sec), 70% 
ethanol (30 sec), 85% ethanol (dip), 95% ethanol (dip), 100% ethanol (2x, dip), 
xylenes (2x, dip). Dehydrated sections were mounted with 1:1 xylenes Cytoseal 
XYL (Thermo Fisher). Brightfield and polarized light images were obtained using 
an Olympus IX70 inverted microscope with an Optronics camera. 
Immunofluorescence 
For analysis of chow and HFD eWAT, sections of eWAT (10 µm) were 
deparaffinized and rehydrated by first being incubated at 55°C for 20 minutes, 
then sequentially submerged in xylenes (2x, 5 min each), 100% ethanol (2x, 5 
min each), 95% ethanol (1 min), 85% ethanol (1 min), 70% ethanol (1 min), 50% 
ethanol (1 min) and lastly distilled water for 1 min. Rehydrated sections were 
blocked with 5% normal goat serum diluted in PBS for 1 hour at room 
temperature, incubated with ACLP (Thermo PA5-23607, 1:100) or perilipin (Cell 
Signaling Technology 9349S, 1:200) overnight at 4°C, washed 3x with PBS-T 
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(PBS with 0.1% Tween 20) (5 min each), incubated with Alexa Fluor 647 
conjugated secondary antibodies (Invitrogen, 1:300), washed 2x with PBS-T then 
2x with PBS (5 min each) and stained tissues were counterstained with DAPI and 
mounted. Tissues were also stained with Alexa Fluor 647 conjugated secondary 
antibody without primary antibody to determine background of 
immunofluorescence. Images were taken at equivalent exposures with a Zeiss 
Observer D1 equipped with an ORCA-Flash 4.0 digital CMOS camera. 
For analysis of myofibroblast differentiation in αSMA-mCherry/Col1-
GFPtpz SVF, cells were plated on chamber slides. The experiment was carried 
out as indicated and on the final day the cells were fixed (10% 
paraformaldehyde, 5 min) and counterstained with DAPI. Images were taken at 
equivalent exposures with a Zeiss Observer D1 equipped with an ORCA-Flash 
4.0 digital CMOS camera. Quantitation of nuclei and fluorescence was performed 
using ImageJ. 
For analysis of differentiation of SVP, SVP were plated on chamber slides 
or embedded in collagen gels. After plating of SVP, images were taken on 
indicated days at equivalent exposures with a Zeiss Observer D1 equipped with 
an ORCA-Flash 4.0 digital CMOS camera. 
For analysis of TGFβ treatment in αSMA-mCherry/Col1-GFPtpz explants, 
explants were cultured under conditions as described above. Upon termination of 
the experiment, explants were washed (2x PBS), fixed (4% paraformaldehyde, 5 
min), washed (2x with PBS), incubated with Hoechst 33342 (Invitrogen) (30 min), 
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washed (3x with PBS), incubated with LipidTOX (Invitrogen) (60 min), washed 
(3x with PBS) and imaged. Images were taken on indicated days at equivalent 
exposures using a Zeiss LSM 700 confocal microscope. 
For live cells analysis of αSMA-mCherry/Col1-GFPtpz SVF, cells were 
isolated from eWAT and cultured overnight. Next morning, cells were given 
treatments and then immediately were imaged every 30 minutes for 96 hours 
with a TE2000-E2 inverted Nikon microscope equipped with the Nikon Perfect 
Focus system enclosed within a controlled humidified environment of 37°C 
temperature and 5% CO2. Images were taken at equivalent exposures. Media 
was refreshed at approximately 48 hours. 
Cell derived matrix generation and isolation 
To generate a cell derived matrix, mouse embryonic fibroblasts (MEF) 
isolated from ACLP–/– and wild type C57Bl/6 mice (246) were cultured until 
confluent. Once confluent, MEFs were then cultured in 1:1 Ham’s F12:DMEM 
with 10% FBS, 1% penicillin/streptomycin supplemented with 50 µg/ml 2-
phospho-L-ascorbic acid (Sigma) to enhance ECM secretion (265). Additionally, 
MEFs were treated with 200 pM TGFβ to promote fibrotic ECM remodeling as 
indicated. Treatment of confluent MEFs was refreshed every 2 days for a total of 
10 days. On day 10 isolation of ECM occurred. To isolate the ECM, ECM was 
washed (PBS), incubated with ECM extraction buffer (25 mM ammonium 
hydroxide, 0.5% Triton-X, PBS) (5 min) (266), washed (4 times with PBS 
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containing 1 mM EDTA) and a final wash (PBS). Following final wash, eWAT 
SVF cells were plated on isolated ECM. 
Statistical analysis 
Data are presented as mean ± S.D. One-way ANOVA with post hoc 
Tukey’s test were used to compare data between two conditions among multiple 
conditions. For analysis comparing two conditions where each control replicate 
was set to 1, a one sample t test was used to determine statistical significance. 
For all other analysis, a Student’s t test was used to determine statistical 
significance. Differences were considered significant when p < 0.05.  
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CHAPTER III – AORTIC CARBOXYPEPTIDASE LIKE PROTEIN ENHANCES 
ADIPOSE TISSUE STROMAL PROGENITOR DIFFERENTIATION INTO 
MYOFIBROBLASTS AND IS UPREGULATED  
IN FIBROTIC WHITE ADIPOSE TISSUE 
Disclaimer: This chapter and portions of Chapter VII. Discussion are adapted 
from Jager, M., Lee, MJ., Li, C., Farmer, S.R., Fried, S.K., and Layne, M.D. 
(2018) Aortic carboxypeptidase like protein enhances adipose tissue stromal 
progenitor differentiation into myofibroblasts and is upregulated in fibrotic white 
adipose tissue. PLoS ONE. 13(5), e0197777. 
 
The WAT vasculature is both the location of ACLP expression (247) and a 
central reservoir of adipose progenitors (24-28, 34). Additionally, others have 
demonstrated that ACLP is a marker of adipose progenitors and ACLP 
expression is rapidly repressed with adipogenic induction (227, 230, 252, 253). 
Previous reports have demonstrated that ACLP expression is increased in lung 
fibrosis and is a mediator of fibroblast to myofibroblast differentiation (226, 250). 
Currently the role of ACLP in the context of WAT fibrosis is unknown, therefore 
given the previous studies, this lead to the hypothesis that ACLP enhanced 
myofibroblast differentiation and repressed adipogenesis in adipose tissue 
progenitors. 
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ACLP is predominately expressed in stromal-vascular progenitors with 
limited expression in mature adipocytes 
Previous studies have documented the kinetics of ACLP expression 
during adipogenesis (227, 232, 252, 268), however it is unclear why ACLP 
expression re-emerges at later time points during adipogenesis. This lead to the 
hypothesis that non-differentiated cells re-expressed ACLP while mature 
adipocytes no longer expressed ACLP. 10T1/2 fibroblasts were differentiated (on 
day 0) into mature adipocytes and protein was harvested every 2 days from day -
2 to day +8 (Fig. 2A). 10T1/2 fibroblasts expressed αSMA and ACLP prior to 
adipogenic induction and these proteins were significantly decreased with 
adipogenic induction on day +2 (7% and 14% of day 0 respectively) (Fig. 2B). As 
anticipated, the expression of both adiponectin and FABP4 increased with 
adipogenic differentiation (Fig. 2B). Notably, ACLP expression increased on day 
4 and continued throughout differentiation (Fig. 2B). To examine if this 
expression was in the mature adipocytes or in the residual undifferentiated 
10T1/2 fibroblasts, the day +8 cells were fractionated by centrifugation based on 
buoyancy. Mature adipocytes (A) expressed the adipocyte markers, FABP4 and 
adiponectin, with limited expression of αSMA and ACLP (Fig. 2B). Non-
differentiated 10T1/2 fibroblasts (ND) expressed ACLP and αSMA, with 
decreased amounts of FABP4 and adiponectin relative to adipocytes (Fig. 2B). 
These findings demonstrate an inverse relationship between ACLP, the 
established progenitor marker αSMA (24, 27), and adipogenesis. 
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Figure 2 – ACLP expression is repressed during adipogenesis. 
A. Scheme of time course for 10T1/2 fibroblast adipogenesis. B. 10T1/2 
fibroblasts were induced to undergo adipogenesis with DMII on day 0. Protein 
was harvested on days -2, 0, +2, +4 and +6. Day +8 cells were fractionated into 
differentiated adipocytes (A) and the non-differentiated 10T1/2 fibroblasts (ND) 
and harvested for protein. Western blot analysis with antibodies against ACLP, α-
SMA, FABP4, adiponectin and CypA. Protein expression was quantified by 
densitometry normalized to CypA expression and all samples were compared to 
day 0 cells or mature adipocyte fraction (n = 3). *, p < 0.05 versus control, one 
way ANOVA with post hoc Tukey’s test for day -2, 0, +2, +4 and +6 samples and 
one sample t-test for fractionated day +8 samples.  
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Recombinant ACLP represses adipogenesis and enhances myofibroblast 
differentiation in progenitors 
ACLP is rapidly down regulated with adipogenesis (Fig. 2B) and is a 
secreted ECM-associated protein (247), this suggested ACLP may regulate 
adipogenic and myofibroblast differentiation pathways. 10T1/2 fibroblasts were 
treated with recombinant ACLP (rACLP) prior to and following adipogenic 
induction (Fig. 3A). Compared with untreated controls, rACLP treatment 
significantly inhibited adipocyte differentiation, indicated by lower expression 
levels of adiponectin and FABP4 (2.7 and 1.8 fold respectively) (Fig. 3B). 
Additionally, compared with untreated controls, rACLP enhanced myofibroblast 
differentiation, as indicated by increased expression levels of ACLP and collagen 
I (Col1) (8.6 and 4.5 fold respectively) (Fig. 3B). rACLP treated cells also 
contained 55% less lipid measured by Oil Red O accumulation (Fig. 3C). These 
findings demonstrate ACLP shifts progenitor differentiation towards myofibroblast 
differentiation. 
ACLP-mediated repression of adipogenesis and enhancement of 
myofibroblast differentiation is dependent on TGFβR signaling 
Previous reports have demonstrated that ACLP signaling exhibited both 
TGFβR dependent and independent activity in lung fibroblasts (250). This 
suggested that the effect of ACLP on adipogenesis could be dependent on 
TGFβR signaling pathways. To test this, 10T1/2 fibroblasts were treated with   
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Figure 3 – ACLP represses adipogenesis.  
A. Scheme of 10T1/2 adipogenesis and rACLP treatment. B. 10T1/2 fibroblasts 
were treated with 30 nM rACLP on days -2, -1, 0, +2 and +4 and induced to 
undergo adipogenesis with DMII on day 0. Protein was harvested on day +6 and 
analyzed by SDS-PAGE and Western blot with antibodies against ACLP, 
collagen, ɑSMA, adiponectin, FABP4, PPARγ and CypA. Protein expression was 
quantified by densitometry normalized to CypA expression and relatively 
compared to control cells (n = 3). *, p < 0.05 versus control, one sample t-test for 
all values. C. 10T1/2 fibroblasts were treated with 30 nM rACLP on days -2, -1, 0, 
+2 and +4 and induced to undergo adipogenesis with DMII on day 0. On day +6 
cells were fixed, stained, imaged and quantified with Oil Red O dye (n = 3). Data 
were normalized relative to control. *, p < 0.05 versus paired control, one sample 
t-test for value. Data presented are expressed as mean ± SD. The scale bar 
represents 2 mm.  
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rACLP in the presence or absence of a TGFβR-1 kinase inhibitor (SB431542) 
prior to and throughout adipogenesis (Fig. 4A). Compared with untreated 
controls, rACLP treatment inhibited adipocyte differentiation, indicated by lower 
expression levels of adiponectin and FABP4 (Fig. 4B). Additionally, compared 
with untreated controls, rACLP enhanced myofibroblast differentiation, as 
indicated by increased ACLP and collagen I (Fig. 4B). The TGFβR inhibitor alone 
did not alter expression of ACLP or αSMA or the ability of cells to undergo 
adipogenesis (Fig. 4B). However, addition of the TGFβR inhibitor blocked rACLP-
mediated induction of ACLP and αSMA expression and rescued adipogenesis as 
indicated by increased FABP4 and adiponectin expression (Fig. 4B). These data 
demonstrate the effect of exogenous ACLP on adipogenesis and myofibroblast 
differentiation is dependent on TGFβR activity. 
ACLP accumulation is increased in regions of adipose tissue fibrosis 
To define the expression of ACLP in fibrotic adipose tissue, epididymal 
white adipose tissue (eWAT) from male mice fed control (chow) or HFD for 16 
weeks was analyzed. Analysis of collagen accumulation by picrosirius red 
staining and imaging with polarized light was performed (269, 270). In chow fed 
mice, collagen was primarily associated with vasculature and was not detected in 
regions proximal to adipocytes (Fig. 5A). In contrast, HFD fed mice exhibited 
extensive pericellular collagen deposition (Fig. 5A). ACLP was strongly 
associated with the vasculature and not adipocytes in chow fed animals (Fig. 5B) 
while ACLP staining co-localized with regions of pericellular collagen deposition 
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Figure 4 – ACLP inhibition of adipogenesis and enhancement of 
myofibroblast differentiation is dependent on TGFβ receptor activity. 
A. Scheme of 10T1/2 fibroblast adipogenesis with the TGFβR kinase inhibitor, 
SB431542, and rACLP treatment. B. 10T1/2 fibroblasts were concurrently treated 
with 30 nM rACLP and vehicle control or 1 µM SB431542, a TGFβ receptor 
kinase inhibitor, on days -2, -1, 0, +2 and +4 as well as induced to undergo 
adipogenesis on day 0. Protein was harvested on day +6 and analyzed by SDS-
PAGE and Western blot with antibodies against ACLP, α-SMA, adiponectin, 
FABP4 and CypA. Protein expression was quantified by densitometry normalized 
to CypA expression and relatively compared to control cells (n = 3). * p < 0.05, ** 
p < 0.01 vs. control, one way ANOVA with post hoc Tukey’s test for all values. 
Data presented are expressed as mean ± SD. 
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Figure 5 – ACLP expression increases in the stromal vascular fraction from 
diet induced fibrotic epididymal adipose tissue. 
A. epididymal adipose tissue from C57BL6/J male mice on chow or high fat diet 
for 16 weeks (n = 3 for each diet group) was excised and fixed with methyl 
Carnoy, stained with picrosirius red and imaged using brightfield (left panels) and 
under polarized light (right panels). B. Tissue sections of epididymal adipose 
tissue following chow or high fat diet were immunostained for ACLP and perilipin 
and counterstained with DAPI. Data are representative of parallel 10 µm 
sections. Closed arrowhead indicates vasculature. Open arrowhead indicates 
pericellular staining. Scale bar represents 100 µm. C. Epididymal adipose tissue 
from C57BL6/J male mice on chow or high fat diet for 16 weeks (n = 3 for each 
diet group) was excised, enzymatically digested, fractionated based on buoyancy 
and then protein lysates were generated of each population. Whole stromal 
vascular fraction lysate was analyzed by SDS-PAGE and Western blot with 
antibodies against ACLP, α-SMA, desmin, SM22, CRP2 and CypA. Protein 
expression was quantified by densitometry normalized to CypA expression and 
relatively compared to higher expressing diet sample. *, p < 0.05 versus chow by 
Student’s t-test. D. Whole adipocyte lysate was analyzed by SDS-PAGE and 
Western blot with antibodies against adiponectin, PPARγ and CypA. Protein 
expression was quantified by densitometry normalized to CypA expression and 
relatively compared to chow. *, p < 0.05 versus chow using Student’s t-test.  
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in adipose tissue isolated from HFD fed mice (Fig. 5B). Consistent with the 
effects of chronic HFD (271), perilipin staining was intermittent in these fibrotic 
regions, likely indicative of adipocyte cell death (Fig. 5B). Previous studies have 
demonstrated that adipocytes secrete numerous ECM proteins in response to 
diet induced obesity (103). In order to determine the response and source of 
ACLP expression to HFD, Western blot analysis on isolated adipocytes and the 
SVF was performed. Following collagenase digestion of chow and HFD eWAT, 
adipocytes and SVF were isolated based on buoyancy and subsequently 
generated into protein extracts. The SVF of chow fed male mice expressed 
significantly less (12% of chow) ACLP compared to SVF of HFD (Fig. 5C). 
Unexpectedly, αSMA exhibited the inverse expression pattern with ACLP in the 
SVF being lower (2% of chow) in SVF of HFD mice (Fig. 5C). To better 
understand this decrease in αSMA in the HFD SVF, analysis of additional smooth 
muscle cell markers was performed. Interestingly, desmin, SM22 and cysteine 
and glycine rich protein-2 (CRP2) expression were equivalent in SVF of chow fed 
and HFD fed mice (Fig. 5C). As expected, isolated adipocytes did not express 
ACLP or αSMA (not shown). Interestingly, while chow and HFD derived 
adipocytes expressed PPARγ at similar levels, adiponectin was expressed in the 
chow fed male mice and its expression was significantly decreased with HFD 
(<1% of chow) (Fig. 5D). These findings demonstrate that ACLP expression 
increases in the SVF in diet-induced fibrotic regions of eWAT. 
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Fibrotic adipose tissue SVF cells depleted of immune cells express ACLP 
Fibrotic ECM deposition in the adipose tissue correlates with infiltration of 
immune cells, including macrophages (13, 119). In order to delineate the cellular 
origin of ACLP and collagens in the fibrotic eWAT, inflammatory and non-
inflammatory sub-populations from eWAT of HFD fed male mice were isolated. 
Adipocytes were separated based on buoyancy and the remaining cells were 
fractionated into CD45+ (immune) and CD45- (SVF) populations (Fig. 6A) (272). 
Transcript levels of ACLP/aebp1, Col1a1, IL-6 and Mcp1 were higher in SVF 
cells compared to immune and adipocyte sub-populations (Fig. 6B). Interestingly 
other major ECM components Col1a2, Col3a1 and Col6a3, were similarly 
expressed in both the SVF and adipocytes and significantly higher compared to 
immune cells (Fig. 6B). SVF cells expressed significantly higher inflammatory 
cytokines, IL-6 and Mcp1, compared to adipocyte and immune sub-populations 
(Fig. 6B). SVF and immune cells expressed similar amounts of CD45 transcript 
and higher levels compared to adipocytes (Fig. 6B). Immune cells expressed 
significantly higher amounts of inflammation marker, F4/80, compared to SVF, 
but similar to adipocytes (Fig. 6B). Adipocytes expressed significantly higher 
adipoq and higher plin1 compared to SVF and immune cells (Fig. 6B). Together 
these results demonstrate ACLP is produced primarily by SVF cells, and not by 
adipocytes or immune cells in the fibrotic eWAT. 
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Figure 6 – SVF depleted of CD45+ cells from fibrotic epididymal adipose 
tissue is the source of ACLP expression. 
A. Scheme of isolating SVF CD45-, SVF CD45+ and adipocyte populations from 
epididymal adipose tissue. B. SVF CD45-, SVF CD45+ and adipocyte 
populations were isolated from epididymal adipose tissue from C57BL6/J male 
mice on chow or high fat diet for 16 weeks (n = 3 for each diet group) and mRNA 
levels were determined by qPCR analysis of fibrosis, inflammation and adipocyte 
markers. * p < 0.05, one way ANOVA with post hoc Tukey’s test for all values. 
Data presented are expressed as mean ± SD. 
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HFD derived SVF cells secreted higher levels of ACLP and have impaired 
adipogenic potential 
Recent studies have demonstrated a HFD induces a shift in the adipose 
progenitor pool towards myofibroblast differentiation (122), however it is unknown 
how HFD impacts ACLP expression and adipogenic phenotype. As SVF cells are 
the source of progenitors (25, 26, 28) and the primary producers of ACLP in the 
fibrotic eWAT (Fig. 6B), additional analysis of the SVF to define the adipogenic 
phenotype in relation to ACLP secretion was performed. SVF cells depleted of 
CD45+ cells were purified from chow and HFD adipose tissue (Fig. 6A) and 
cultured for 24 hours. The media was collected, clarified and analyzed by 
Western blot for secreted ACLP. Compared with chow-derived SVF, HFD derived 
SVF secreted increased amounts of ACLP into the media (Fig. 7A). HFD derived 
SVF cells exhibited impaired adipogenesis compared to chow derived SVF cells, 
as indicated by significantly lower expression of adiponectin and FABP4 (9.0 and 
4.3 fold respectively), however there was similar expression of perilipin (Fig. 7B). 
Consistent with Western blot analysis, lipid droplet accumulation by oil red O 
staining was performed. Compared with controls, HFD derived SVF accumulated 
52% less lipid (Fig. 7C). These results demonstrate that HFD-induced obesity 
increases the secretion of ACLP from SVF. Furthermore, the HFD-induced 
obesity decreases the adipogenic potential of the total SVF. Collectively this 
supports the inverse relationship of ACLP and adipogenesis. 
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Figure 7 – High fat diet reduces adipogenic potential of stromal-vascular 
cells. 
A. Epididymal adipose tissue from C57BL6/J male mice on chow or high fat diet 
for 16 weeks (n = 3 for each group) was excised, enzymatically digested and 
depleted of CD45+ cells. SVF cells were then cultured for 24 hours in 10% FBS 
DMEM and subsequently media was collected and analyzed by SDS-PAGE and 
Western blot with antibodies against ACLP. B. SVF cells were isolated as above 
and cultured for 10 days in 10% FBS DMEM, DMII was given on day 2 and cell 
lysates were harvested on day 10. Cell lysates were analyzed by SDS-PAGE 
and Western blot with antibodies against adiponectin, perilipin and FABP4. 
Protein expression was quantified by densitometry normalized to CypA 
expression and relatively compared to chow cells (n = 3). * p < 0.05, Student’s t-
test used for all values. C. SVF cells were isolated as above and were cultured 
(100,000 cells/12well) until confluent, and then induced to undergo adipogenesis 
with DMII 2 days after confluent. Oil Red O staining and imaging was performed 
8 days following adipogenic induction (n = 3). * p < 0.05, Student’s t-test used for 
all values. The scale bar represents 100 µm. Data presented are expressed as 
mean ± SD. 
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ACLP is downregulated during adipogenesis in human adipose stromal 
cells 
Human adipose tissue depots differentially respond to the stresses of 
obesity (102, 273). In contrast to the sWAT depot, the omental WAT (oWAT) is 
susceptible to fibrotic changes following chronic excess caloric intake (122, 126). 
Little is currently known about the expression and function of ACLP in human 
adipogenesis. To determine kinetics of ACLP expression during adipogenesis, 
human adipose stromal cells (hASC) from oWAT and sWAT were induced to 
differentiate with serum-free complete differentiation media (CDM) (Fig. 8A) (66). 
ACLP and αSMA protein expression is detected in undifferentiated oWAT hASC 
but their expression decreases 2 days following adipogenic induction (Fig. 8B). 
Expression of each re-emerged 8 and 15 days concomitantly with the 
appearance of fatty acid binding protein 4 (FABP4) (Fig. 8B). A similar early 
expression pattern of ACLP and αSMA was observed in differentiating sWAT 
hASC (Fig. 8C) but ACLP was only minimally expressed by day 15. These 
observations demonstrate that ACLP expression is higher throughout 
adipogenesis in oWAT hASC as compared to sWAT hASC, providing further 
evidence that the oWAT hASC are resistant to adipogenesis. 
Recombinant ACLP represses human adipose stromal cells adipogenesis 
and promotes myofibroblast differentiation  
Given that sWAT hASC are more adipogenic compared to oWAT hASC 
(Fig. 8B, C) and ACLP inhibits adipogenesis (Fig. 4B), this lead to the question  
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Figure 8 – Recombinant ACLP inhibits adipogenesis and enhances 
myofibroblast differentiation in human adipose stromal cells. 
A. Scheme of time course for adipogenesis of hASC. B. hASC derived from 
subcutaneous adipose depots were induced to undergo adipogenesis with CDM 
on day 0. Protein was harvested on days 0, +1, +2, +8 and +15. Protein 
expression was analyzed using SDS-PAGE and Western blot with antibodies 
against ACLP, α-SMA, FABP4 and cyclophilin-A (n = 3). C. Omental hASC were 
induced to undergo adipogenesis with CDM on day 0. Protein was harvested on 
days 0, +1, +2, +8 and +15. Protein expression was analyzed using SDS-PAGE 
and Western blot with antibodies against ACLP, α-SMA, FABP4 and cyclophilin-
A (n = 3). D. Scheme of adipogenesis for hASC and rACLP treatment. E. 
Subcutaneous hASC were treated with 30 nM rACLP on days -2, -1 and 0 and 
induced to undergo adipogenesis with CDM on day 0 and +4. Protein was 
harvested on day +15 and analyzed by SDS-PAGE and Western blot with 
antibodies against collagen, α-SMA, perilipin, FABP4 and CypA (n = 3). F. 
Subcutaneous hASC were treated with 30 nM rACLP on days -2, -1, and 0 and 
induced to undergo adipogenesis with CDM on day 0 and +4. On day +15 cells 
were fixed, stained, imaged and quantified with Oil Red O dye (n = 5). Data were 
normalized relative to control. * p < 0.05 versus control. Data presented are 
expressed as mean ± SD. The scale bar represents 2 mm.  
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that ACLP may inhibit adipogenesis in sWAT hASC. To test whether rACLP 
directs the fate of human progenitors, individual sWAT hASC isolates were 
cultured in media containing rACLP (30 nM) prior to adipogenic induction, during 
the commitment phase (274) (Fig. 8D). In comparison to untreated control cells, 
treated cells expressed lower amounts of perilipin and FABP4 (2/3 and 2/3 cell 
isolates respectively) and higher amounts of αSMA and Col1 (3/3 and 1/3 cell 
isolates respectively) at 8 and 15 days following differentiation (Fig. 8E). 
Consistent with an attenuation of adipogenesis, treated cells also contained less 
lipid (Fig. 8F). While rACLP treatment can dampen adipogenesis, its effect on 
sWAT hASC varied from donor to donor. 
In summary, ACLP enhances the differentiation of mouse and human 
adipose progenitors to a myofibroblast phenotype at the expense of adipogenic 
differentiation. Importantly, ACLP is derived from non-adipocytes and non-
immune cells, and is greatly increased with chronic HFD and localizes with peri-
cellular ECM deposition in fibrotic WAT. ACLP activity may represent a novel 
therapeutic target that is independent of inflammation in ameliorating WAT 
fibrosis.  
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CHAPTER – IV REGULATION OF ACLP EXPRESSION AND SIGNALING BY 
ADIPOGENIC STIMULI  
Repression of ACLP expression requires combination treatment with 
dexamethasone, IBMX and insulin 
While in vitro activation of adipogenesis can be achieved through addition 
of adipogenic stimuli, such as glucocorticoids, cyclic AMP agonists, and insulin 
(275-277), these stimuli also inhibit myofibroblast differentiation pathways (278). 
For example, IBMX, a cyclic nucleotide phosphodiesterase inhibitor, reduces 
collagen expression in differentiating fibroblasts (279), while dexamethasone, a 
glucocorticoid receptor agonist, attenuates TGFβ-Smad2/3 signaling in 
fibroblasts (278). Because ACLP protein expression was rapidly repressed 
following DMI treatment (Fig. 2B) and DMI affects several myofibroblast 
differentiation pathways, analysis of how individual pathways activated by DMI 
would be responsible for ACLP protein expression was performed. In order to 
determine whether a single component of DMI has a dominant effect on ACLP 
protein expression, 10T1/2 fibroblasts were treated with individual, combinations 
and the complete DMI cocktail combination for 48 hours, and protein expression 
was analyzed at 24 and 48 hours. 24 hours after treatment, ACLP protein 
expression significantly decreased with insulin and combinations of 
dexamethasone and insulin or IBMX and insulin however decrease was most 
pronounced with complete DMI cocktail (Fig. 9). ACLP protein expression 
significantly decreased with combination of dexamethasone and IBMX and again 
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Figure 9 – Repression of ACLP expression requires combination treatment 
with dexamethasone, IBMX and insulin. 
10T1/2 fibroblasts were treated with individual and various combinations of DMI 
adipogenic cocktail for 48 hours. At 24 and 48 hours, cells were harvested and 
analyzed by SDS-PAGE and Western blot with antibodies against ACLP and 
CypA. Data presented are representative of 3 separate experiments. Data were 
normalized relative to untreated control for each day. * indicates significance (p < 
0.05) versus control cells. ** indicates significance (p < 0.01) versus control cells. 
Data are expressed as mean ± SD. 
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with complete DMI cocktail 48 hours after treatment (Fig. 9). These results 
demonstrate that while individual DMI activated signaling pathways can 
temporarily repress ACLP protein expression, the complete adipogenesis cocktail 
of DMI was required to completely repress ACLP protein expression. 
Partial Aebp1 knockout does not effect adipogenic gene expression of 
stromal-vascular cells 
Previous reports have demonstrated that αSMA controls stem cell 
differentiation (280) as well as adipose progenitor differentiation (87, 88, 281). 
Furthermore, ACLP protein expression precedes αSMA expression during 
fibroblast to myofibroblast transition, and repressing ACLP blunts this 
enhancement (250). This collectively suggests that ACLP expression may 
enhance myofibroblast gene expression and is repressive to adipogenic gene 
expression. To determine the effect of ACLP gene expression on adipogenic 
gene expression, eWAT SVF cells from Cre-Aebp1flx/flx male mice were 
isolated, then treated with tamoxifen to induce knockout of Aebp1 gene 
expression (Fig. 10A). After a tamoxifen washout period, transcript levels of 
Aebp1, fibrotic and adipogenic transcription factors were analyzed. Aebp1 gene 
expression was significantly decreased with tamoxifen induced genetic 
recombination (51% decreased expression relative to control), while fibrotic or 
adipogenic genes were not affected (Fig. 10B). These preliminary results suggest 
that a partial loss of ACLP does not affect myofibroblast or adipocyte potential in 
adipose progenitors. Notably, Aebp1 knockdown, while significant, was modest 
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Figure 10 – Partial knockout of AEBP1 gene expression does not effect 
levels of fibrotic or adipogenic transcripts. 
A. Epididymal adipose tissue stromal-vascular cells from a 14-week old Cre-
Aebp1flx/flx C57BL6/J male mice were isolated then cultured in 10% FBS DMEM 
treated with or without Tamoxifen for 3 days to induce recombination of the 
Aebp1 gene. mRNA was harvested following 4 day tamoxifen washout period. B. 
mRNA was analyzed with RT-PCR and qPCR to quantitate gene expression of 
Aebp1, Acta2, Col1a1, Col6a1, Pparγ, C/ebpα, C/ebpβ , C/ebpγ and Chop. * 
indicates significance (p < 0.05) versus control cells. Experiment was performed 
in triplicate (1 mouse, 3 wells per condition). Student’s t-test was used for all 
values. Data presented are expressed as mean ± SD. 
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and may not be sufficient to diminish its function. 
ACLP-mediated myofibroblast differentiation is partially dependent on 
ROCK activity 
Inhibition of adipogenesis and enhancement of myofibroblast 
differentiation by ACLP signaling can be blocked by small molecule inhibition of 
the TGFβR kinase (Fig. 4). While the TGFβR is at the center of pro-fibrotic 
signaling pathways and also controls adipogenesis (73, 127), numerous other 
signaling pathways contribute to adipose tissue progenitor differentiation (38). 
For example, actin cytoskeletal dynamics that converge on and depend on 
ROCK activity also promote myofibroblast differentiation (190, 192) and repress 
adipogenesis via MRTFA activation (87, 88, 281). ROCK activity can be 
mediated by both TGFβR dependent and independent signaling activity (282). 
ROCK activation results in nuclear translocation of MRTFA and activation of SRF 
(86). Previous reports have demonstrated that ACLP partially enhances 
myofibroblast differentiation through MRTFA transcriptional activity (250). As 
ACLP is able to activate signaling pathways that regulate myofibroblast and 
adipogenic pathways, this supports that ACLP signaling may be dependent on 
ROCK activity. To determine if ACLP signals via ROCK activity, 10T1/2 
fibroblasts were treated with rACLP in the presence or absence of a ROCK 
inhibitor (Y27632) prior to and throughout adipogenesis (Fig. 11A). Compared 
with untreated controls, rACLP treatment inhibited adipocyte differentiation, 
indicated by lower expression levels of PPARγ (Fig. 11B). Additionally, compared 
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Figure 11 – ACLP inhibition of adipogenesis is independent of ROCK 
activity.  
A. Scheme of 10T1/2 fibroblast adipogenesis with the ROCK inhibitor, Y27632, 
and rACLP treatment. B. 10T1/2 fibroblasts were concurrently treated with 3.75 
µg/ml rACLP and vehicle control or 5 µM Y27632, a ROCK kinase inhibitor, on 
days -2, -1, 0, +2, +4 and +6 as well as induced to undergo adipogenesis on day 
0. Protein was harvested on day +8 and analyzed by SDS-PAGE and Western 
blot with antibodies against PPARγ, ACLP, αSMA, Col1 and CypA. 
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with untreated controls, rACLP enhanced myofibroblast differentiation, as 
indicated by increased ACLP, αSMA and collagen I (Fig. 11B). The ROCK 
inhibitor alone did not alter expression of ACLP, αSMA or collagen I or the ability 
of cells to undergo adipogenesis (Fig. 11B). Additionally the ROCK inhibitor did 
not attenuate rACLP-mediated induction of ACLP and collagen I or blunt 
adipogenesis as indicated by increased PPARγ (Fig. 11B). Interestingly ROCK 
inhibition blunted rACLP-mediated induction of αSMA expression (Fig. 11B), 
which is consistent with ROCK mediated activation of αSMA (283, 284). These 
data demonstrate the effect of exogenous ACLP on adipogenesis is independent 
of ROCK activity but is partially responsible for αSMA expression with 
myofibroblast differentiation. 
ACLP-mediated myofibroblast differentiation is partially dependent on FAK 
activity 
An additional signaling pathway that controls myofibroblast differentiation 
is through activation of FAK via matrix interactions with integrins (211). In lung 
fibroblasts, ACLP partially controls myofibroblast differentiation in a TGFβR 
dependent and independent manner through an unknown receptor (250). 
Additionally ACLP is hypothesized to effect ECM mechanical properties as 
individuals lacking ACLP have abnormal connective tissues (237, 238). Together, 
this suggests ACLP potentially associates with the ECM and activates integrin-
FAK either through direct activation or indirectly through modulation of ECM 
mechanical properties. To test this 10T1/2 fibroblasts were treated with rACLP in 
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the presence or absence of a FAK inhibitor (FAK 14) for 96 hours (Fig. 12A). 
Compared with untreated controls, rACLP treatment modestly increased αSMA 
and collagen I (Fig. 12B). The FAK inhibitor alone repressed expression of 
collagen I but not αSMA (Fig. 12B). The FAK inhibitor attenuated rACLP-
mediated increase in αSMA, but interestingly the rACLP-mediated increase in 
collagen I was not affected by FAK inhibition (Fig. 12B). These preliminary data 
demonstrate ACLP mediated increase of αSMA expression during myofibroblast 
differentiation is partially dependent on FAK activity. 
Previous analysis suggests ACLP signaling is partially dependent on FAK 
activity. Notably FAK activity is sensitive to ECM rigidity, where increased rigidity 
enhances FAK activity (285). Previous experiments analyzing ACLP mediated 
FAK activity were performed on rigid tissue culture plastic and may not be 
physiologically relevant to FAK activity in the context of differentiation. 
Additionally, WAT fibrosis results in increased ECM rigidity (125, 286) and ACLP 
expression is increased with WAT fibrosis (Fig. 5), therefore this suggests that 
ACLP mediated FAK activity on myofibroblast differentiation may depend on 
ECM rigidity. To test this, 10T1/2 fibroblasts were cultured on 6 kPa and 25 kPa 
collagen gels and then treated with rACLP in the presence or absence of a FAK 
inhibitor (FAK 14) for 96 hours (Fig. 13A). Compared with untreated controls, 
rACLP treatment enhanced αSMA and ACLP on both 6 and 25 kPa gels (Fig. 
13B). The FAK inhibitor alone did not affect ACLP or αSMA protein expression 
(Fig. 13B). The FAK inhibitor did not attenuate ACLP increase of αSMA or ACLP 
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Figure 12 – ACLP enhancement of myofibroblast differentiation is partially 
dependent on FAK activity. 
A. Scheme of 10T1/2 fibroblast myofibroblast differentiation with the FAK 
inhibitor, FAK 14, and rACLP treatment. B. 10T1/2 fibroblasts were concurrently 
treated with 3.75 µg/ml rACLP and vehicle control or 1 µM FAK 14, a FAK 
inhibitor, on days 0 and 2 as well. Protein was harvested on day 4 and analyzed 
by SDS-PAGE and Western blot with antibodies against Col1, αSMA and CypA.  
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Figure 13 – ACLP enhancement of myofibroblast differentiation is 
independent of FAK activity when cultured on collagen gels. 
A. Scheme of 10T1/2 fibroblast myofibroblast differentiation with FAK 14 and 
rACLP treatment. B. 10T1/2 fibroblasts were cultured on 6 kPa or 25 kPa 
collagen gels then were concurrently treated with 3.75 µg/ml rACLP and vehicle 
control or 1 µM FAK 14, a FAK inhibitor, on days 0 and 2 as well. Protein was 
harvested on day 4 and analyzed by SDS-PAGE and Western blot with 
antibodies against ACLP, αSMA and CypA. 
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on 6 or 25 kPa gels (Fig. 13B). Together, these preliminary studies are 
inconclusive. It does suggest ACLP signaling can be mediated via FAK activity 
and is dependent on ECM rigidity, but further studies are required. 
ACLP-mediated repression of adipogenesis is independent of FAK activity 
In addition to controlling myofibroblast differentiation, increased FAK 
activity is anti-adipogenic (221, 222). While ACLP signaling regulation of 
myofibroblast differentiation is partially dependent on FAK activity in certain 
contexts, it may regulate adipogenesis via FAK activity. To test this, 10T1/2 
fibroblasts were treated with rACLP in the presence or absence of a FAK inhibitor 
(FAK 14) prior to and throughout adipogenesis (Fig. 14A). Compared with 
untreated controls, rACLP treatment inhibited adipocyte differentiation, indicated 
by decreased expression levels of adiponectin and FABP4 (Fig. 14B). 
Additionally, compared with untreated controls, rACLP enhanced myofibroblast 
differentiation, as indicated by increased αSMA and collagen I (Fig. 14B). 
Interestingly the FAK inhibitor alone did not alter expression of αSMA or collagen 
I, however it did enhance adipogenesis as indicated by increased adiponectin 
and perilipin relative to untreated control (Fig. 14B). FAK inhibition did not effect 
ACLP signaling as it did not enhance adipogenesis or attenuate αSMA or 
collagen expression (Fig. 14B). In contrast to the ACLP partial dependence of 
FAK on myofibroblast differentiation (Fig. 12B), these preliminary results 
demonstrate ACLP mediated inhibition of adipogenesis is independent of FAK 
activity. 
  70 
 
Figure 14 – ACLP inhibition of adipogenesis is independent of FAK activity. 
A. Scheme of 10T1/2 fibroblast adipogenesis with the FAK inhibitor, FAK 14, and 
rACLP treatment. B. 10T1/2 fibroblasts were concurrently treated with 3.75 µg/ml 
rACLP and vehicle control or 1 µM FAK 14, a FAK inhibitor, on days -2, -1, 0, +2, 
+4 and +6 as well as induced to undergo adipogenesis on day 0. Protein was 
harvested on day +8 and analyzed by SDS-PAGE and Western blot with 
antibodies against Col1, αSMA, adiponectin, perilipin and CypA.  
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CHAPTER V – STROMAL-VASCULAR CELLS CONTRIBUTE TO ADIPOCYTE 
AND MYOFIBROBLAST EXPANSION 
WAT fibrosis is hypothesized to contribute to metabolic dysfunction by 
promoting myofibroblast differentiation of adipose progenitors, thereby limiting 
the extent of adipocyte hyperplasia (90, 119). Fibroblasts are heterogeneous and 
many types can give rise to myofibroblasts. Lineage tracing studies have 
identified SVF sub-populations that are adipogenic and also contribute to the 
myofibroblast population in skin scleroderma (124) and WAT fibrosis (122). While 
myofibroblasts are classically defined as αSMA and collagen I expressing 
fibroblasts (127, 136) little is relatively known about the WAT myofibroblast. 
αSMA-/Col1+ and αSMA-/Col1- stromal-vascular fraction cells undergo 
myofibroblast differentiation at equal capacity 
It is likely that multiple WAT SVF cells are adipogenic and can undergo 
myofibroblast differentiation. To test this, freshly isolated eWAT SVF from αSMA-
mCherry/Col1-GFPtpz male mice were imaged every 30 minutes for 96 hours 
following TGFβ treatment. SVF cells from αSMA-mCherry/Col1-GFPtpz male 
mice were analyzed to visualize promoter activity of myofibroblast markers, 
αSMA and collagen I (127, 136). Myofibroblasts were defined as cells that co-
express αSMA (αSMA+) and collagen I (Col1+). TGFβ was utilized to drive 
myofibroblast differentiation as it is a master regulator of fibrosis across 
numerous tissues (161) and its expression is increased in obese tissues (162). At 
hour 0, the SVF was composed of a mixture of αSMA-/Col1- and αSMA-/Col1+ 
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cells, however there were no αSMA+ cells observed. TGFβ elicited an 
appreciable myofibroblast differentiation response where at 96 hours following 
TGFβ treatment, the eWAT SVF proliferated and the majority of SVF cells 
expressed αSMA and Col1 (Fig. 15A). To trace the origin of myofibroblasts, 
αSMA+/Col1+ co-expressing SVF were identified at hour 96 and then tracked to 
hour 0 to determine original cell state (Fig. 15B). Myofibroblasts originated from 
αSMA-/Col1- cells at comparable frequency to αSMA-/Col1+ cells (Fig. 15C). 
These preliminary results indicate that eWAT SVF can undergo myofibroblast 
differentiation at equal capacity regardless of original collagen expression state. 
αSMA-/Col1+ and αSMA-/Col1- stromal-vascular fraction cells undergo 
adipogenesis at equal capacity 
Adipocytes can originate from numerous types of adipose progenitors (24, 
25, 27, 28, 96). Recent studies have demonstrated that a PDGFRα+ sub-
population of SVF, that normally differentiate into adipocytes (25), can undergo 
myofibroblast differentiation with chronic obesity (122). The previous analysis 
demonstrated that multiple SVF sub-populations can contribute to myofibroblast 
expansion, whether these SVF sub-populations can also undergo adipogenesis 
was examined. To test this, freshly isolated eWAT SVF cells from αSMA-
mCherry/Col1-GFPtpz male mice were cultured overnight. Following overnight 
culturing, SVF were treated with DMII and then imaged every 30 minutes for 96 
hours, with a media change at 48 hours. Adipogenesis was defined as a cell with 
multi-locular lipid droplets as observed with brightfield microscopy. Adipogenic  
  73 
Figure 15 – αSMA-/Col1- and αSMA-/Col1+ stromal-vascular cells have 
equal capacity to co-express αSMA and collagen. 
Epididymal adipose tissue stromal-vascular cells from 10-week old αSMA-
mCherry/Col1-GFPtpz C57BL6/J male mice were isolated then cultured in media 
with 500 pM TGFβ for 96 hours with a media change at 48 hours. Fluorescence 
and brightfield images were taken every 30 minutes for 4 fields of view for 96 
hours. A. Representative merged fluorescence and brightfield image of first 
image (hour 0) and final image (hour 96). Myofibroblast lineage was determined 
by quantifying original cell state of αSMA+/Col1+ cells at hour 96. B. 
Representative image of tracking a single cell becoming a αSMA+/Col1+ cell. C. 
20 αSMA+/Col1+ cells were randomly selected at 96 hours per field of view and 
were observed back to hour 0. 4 fields of view were analyzed. Original cell type 
was quantified normalized to αSMA-/Col1- cell count. 
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induction elicited an appreciable adipogenic response where at hour 0 the 
majority of eWAT SVF cells were lipid droplet free but 96 hours following 
adipogenic induction, there was an increase in lipid droplet positive SVF cells 
(Fig. 16A). To trace the origin of adipocytes, lipid droplet positive SVF cells were 
identified at hour 96 and then were tracked to hour 0 to determine original cell 
state (Fig. 16B). Adipocytes originated from αSMA-/Col1- cells at a comparable 
frequency to αSMA-/Col1+ cells (Fig. 16C). These preliminary results indicate 
that both αSMA-/Col1- cells and αSMA-/Col1+ cells can undergo adipogenesis at 
equal capacity. 
αSMA+ stromal-vascular particulate cells do not proliferate with culturing 
on tissue culture plastic 
Previous results have demonstrated that αSMA-/Col1- and αSMA-/Col1+ 
SVF cells have equal capacity to undergo differentiation into myofibroblast (Fig. 
15) and adipocytes (Fig. 16). Interestingly, αSMA expressing cells were not 
readily observed as part of the SVF (Fig. 15, 16). While the SVF by definition 
contains a vascular cell fraction, it is not apparent if vascular cells, namely 
smooth muscle and endothelial cells, are isolated with standard SVF extraction 
protocols (24, 34). Previous reports have demonstrated that adipocytes originate 
from an αSMA+ cell lineage (24, 27). In order to analyze αSMA+ SVF cells, intact 
vascular fragments which contain αSMA+ cells were studied (24). iWAT SVP 
were freshly isolated by enzymatic digestion and vessel fragments larger than 
100 µm were cultured on tissue culture plastic and imaged for 5 days. At day 1,  
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Figure 16 – αSMA-/Col1- and αSMA-/Col1+ stromal-vascular cells have 
equal capacity to become differentiated adipocytes. 
Epididymal adipose tissue stromal-vascular cells from 10-week old αSMA-
mCherry/Col1-GFPtpz C57BL6/J male mice were isolated then cultured in 10% 
FBS DMEM and induced to undergo adipogenesis with DMI for 96 hours with a 
media change at 48 hours. Fluorescence and brightfield images were taken 
every 30 minutes for 4 fields of view for 96 hours. A. Representative merged 
fluorescence and brightfield image of first image (hour 0) and final image (hour 
96). Adipocyte lineage was determined by quantifying original cell state of 
differentiated adipocyte at hour 96. B. Representative image of tracking a single 
cell becoming a differentiated adipocyte. C. 20 adipocytes were randomly 
selected at the 96 hours per field of view and were tracked back to hour 0. 4 
fields of view were analyzed. Original cell type was quantified normalized to 
αSMA-/Col1- cell count.  
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αSMA+/Col1- cells were observed as a part of an intact vasculature fragment 
surrounded by perivascular αSMA-/Col1+ cells (Fig. 17). On days 3 and 5, 
αSMA-/Col1+ cells increased and migrated on to the tissue culture plastic away 
from the vasculature (Fig. 17). In contrast, there was no observed increase or 
migration of αSMA+/Col1- cells (Fig. 17). With the intention of examining the 
response to a fibrotic stimulus, addition of TGFβ resulted in contraction and 
peeling of SVP from plastic (not shown) which prevented more detailed analysis. 
αSMA+ stromal-vascular cells dissociate from vasculature with TGFβ 
stimulation 
Previous results utilizing the SVP model demonstrated that αSMA-/Col1+ 
cells rapidly expand with culturing on plastic (Fig. 17), however modeling a 
fibrotic response with TGFβ was not feasible with tissue culture plastic. In order 
to observe the response of αSMA+ cells to both adipogenic and fibrotic stimuli, 
SVP were embedded in collagen gels (77, 80). iWAT SVP were freshly isolated 
as above, cultured in collagen gels and imaged on day 1, 3, and 6. Additionally, 
SVP were treated with adipogenic stimuli, DMI or insulin (24), or fibrotic stimuli, 
TGFβ. With either DMI or insulin, there was no observed adipogenesis (Fig. 18). 
Adipogenesis was assessed by brightfield microscopy (not shown). TGFβ 
stimulus resulted in dissociation of the SVP structure and an increase in 
αSMA+/Col1+ cells at day 3 and 6 (Fig. 18). Importantly, this 
immunofluorescence microscopy was not confocal so analysis of αSMA and Col1  
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Figure 17 – Perivascular Col1+ cells in stromal vascular particulates 
undergo rapid expansion in vitro. 
Inguinal adipose tissue stromal-vascular particulates were isolated from 10-week 
old αSMA-mCherry/Col1-GFPtpz C57BL6/J male mice and cultured with 10% 
FBS DMEM on tissue culture plastic for 5 days with media changes every 2 days. 
On days 1, 3 and 5, stromal-vascular particulates were imaged using 
fluorescence microscopy. 
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Figure 18 – TGFβ disrupts the structure of isolated inguinal adipose tissue 
vasculature in 3D culture. 
Inguinal adipose tissue stromal-vascular particulates were isolated from 10-week 
old αSMA-mCherry/Col1-GFPtpz C57BL6/J male mice and embedded in 
collagen gels and cultured with 10% FBS DMEM for 6 days. The day following 
gel embedding (Day 1), SVP were treated with DMI, 10 µg/ml insulin or 200 pM 
TGFβ with media changes performed every 2 days. On days 1, 3 and 6 stromal-
vascular particulates were imaged using fluorescence microscopy. Arrows show 
cells migrating into gel. Each day images were taken at identical exposure. 
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co-expression is limited. These preliminary results suggest that fibrotic stimuli 
increases motility of αSMA+ vascular cells however these cells are not 
adipogenic under these conditions. 
αSMA-/Col1+ stromal-vascular cells migrate with TGFβ treatment in an 
explant model 
WAT explant models have been used to analyze aspects of WAT 
physiology (287-289), however they have not been utilized in analysis of WAT 
fibrosis. Given that various SVF cells from αSMA-mCherry/Col1-GFPtpz mice are 
able to differentiate into adipocytes and myofibroblasts (Fig. 15,16), an explant 
culture from these mice was utilized to model a response to fibrotic stimuli. To 
develop this model, eWAT from αSMA-mCherry/Col1-GFPtpz mice were cultured 
in the presence or absence of TGFβ for 96 hours. Explants were then analyzed 
by confocal microscopy with counterstains against lipids and nuclei. TGFβ 
treated explants had a higher number of αSMA-/Col1+ cells and fewer 
adipocytes (Fig. 19). Across both treatments there was a decrease of αSMA+ 
cells (Fig. 19). Importantly, there was increased incidence of αSMA-/Col1+ cells 
with TGFβ treatment, however this was not consistent in all areas observed. 
Furthermore, imaging was approximately 200 µm thick starting from the tissue 
edge. These preliminary data suggest that TGFβ treatment results in increased 
expansion of αSMA-/Col1+ cells and decrease in adipocytes, however further 
optimization is required to properly quantitate changes. 
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Figure 19 – Collagen expressing cells in epididymal adipose tissue 
increase following TGFβ treatment. 
Epididymal adipose tissue explants were isolated from 10-week old αSMA-
mCherry/Col1-GFPtpz C57BL6/J male mice were cultured in suspension with 
10% FBS DMEM with or without 200 pM TGFβ for 4 days with a media change 
every 2 days. Tissues were briefly fixed then incubated with LipidTOX and DAPI 
and then imaged using confocal microscopy. Arrows show Col1+ cells. Images 
are a projection of 10 images that are 10 µm apart. Images were taken with 
identical exposure.  
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Stromal-vascular cells increase expression of αSMA and collagen with 
ACLP and TGFβ treatment 
Earlier studies have demonstrated that ACLP enhances myofibroblast 
differentiation and attenuates adipogenesis (Fig. 4C,D). In addition, the SVF 
undergoes myofibroblast differentiation in response to fibrotic stimuli resulting in 
an increase in αSMA and collagen I expressing and co-expressing cells (Fig. 15). 
ACLP likely induces a fibrotic response in SVF, as defined by increase in αSMA 
and collagen I expression in SVF cells. To test this, SVF cells from αSMA-
mCherry/Col1-GFPtpz mice were isolated and then treated with rACLP and 
TGFβ for 96 hours. SVF was then analyzed with fluorescence microscopy and 
counterstained to visualize nuclei. Total fluorescence intensity of mCherry and 
GFPtpz per field was quantified and divided by total number of nuclei to 
normalize. αSMA expression per cell increased with both rACLP and TGFβ 
treatment (2.7 and 2.2 fold increase respectively) (Fig. 20). Col1 expression per 
cell was significantly higher in ACLP treated SVF cells (1.7 fold increase) 
compared to control (Fig. 20). Interestingly, TGFβ treatment did not result in 
significantly higher Col1 expression per cell (Fig. 20). While both ACLP and 
TGFβ enhanced αSMA and collagen I expression, this increase was not uniform 
across all SVF cells (Fig. 20). Interestingly, very few SVF cells co-expressed both 
αSMA and collagen I. These data demonstrate that ACLP enhances αSMA and 
collagen I expression in SVF cells, however the response is heterogeneous 
across the SVF. 
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Figure 20 – ACLP increases collagen and αSMA reporter expression in 
stromal-vascular cells. 
Epididymal adipose tissue stromal-vascular cells from 8-week old αSMA-
mCherry/Col1-GFPtpz C57BL6/J male mice were isolated then cultured in 10% 
FBS DMEM in the presence or absence of 3.75 µg/ml rACLP or 200 pM TGFβ for 
4 days with a media change every 2 days. On day 4, cells were briefly fixed and 
counterstained with DAPI and imaged using fluorescence microscopy. Green 
arrows indicate Col1-GFPtpz+ cells. Red arrows indicate αSMA-mCherry+ cells. 
4 fields of each treatment condition were analyzed. Fluorescence per cell is 
defined as the fluorescence intensity per field divided by the number of DAPI per 
field. All values were normalized to respective control fluorescence per cell. * 
indicates significance (p < 0.05) versus untreated control cells. 
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CHAPTER VI – DEVELOPING A MODEL TO STUDY FIBROTIC 
EXTRACELLULAR MATRIX REMODELING 
WAT fibrosis is a result of multiple signaling pathways induced by hypoxia, 
cell death, and inflammation (17, 31, 102). The current understanding of ECM 
remodeling and deposition with respect to WAT fibrosis remains relatively limited 
(18). In mice, WAT fibrosis develops following a multi-week to months-long 
treatment with HFD (122, 132). This slow rate of disease progression impedes 
the dissection of individual mediators and pathways that control WAT fibrosis. 
The goal of this aim was to develop models of WAT fibrosis to examine questions 
related to ECM changes and their contributions to WAT fibrosis. 
The inguinal adipose tissue undergoes increased extracellular matrix 
deposition with TGFβ treatment in an explant model 
In addition to the previous analysis (Fig. 5), others have demonstrated that 
obesity mediated WAT fibrosis is characterized with abnormal pericellular ECM 
deposition (17, 102, 134). A major advantage of the WAT explant model is it can 
analyze individual cellular responses to fibrotic stimuli over a short period of time 
(Fig. 19) relative to in vivo WAT fibrosis development (132). While cellular 
contributions can be potentially tracked in the explant model, it could also be 
utilized to analyze ECM deposition in WAT in a fibrotic context. In order to 
analyze ECM deposition, iWAT explants were cultured under explant culture 
conditions for up to 10 days in the presence or absence of fibrotic stimuli, TGFβ 
or ACLP. Due to the delayed response of fibrotic remodeling in WAT (124), initial 
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studies were performed over 10 days to provide time for ECM fibrosis and 
remodeling. At day 10, iWAT explants were fixed and processed for histology. 
Collagen accumulation was analyzed by picrosirius red staining and imaging with 
polarized light. Fibrillar collagen is visualized as red and orange under polarized 
light (269, 270). At day 0 and day 10, untreated control collagen deposition in 
iWAT explants was perivascular and associated with septa (Fig. 21). In contrast, 
day 10 ACLP and TGFβ treated iWAT explants exhibited increased perivascular 
and septa collagen deposition (Fig. 21). These data suggest that the WAT 
explant model could be utilized to observe ECM changes in WAT following 
fibrotic stimulus. 
The epididymal adipose depot undergoes increased pericellular collagen 
deposition with TGFβ treatment 
While previous analysis demonstrated the iWAT can undergo ECM 
deposition with fibrotic stimuli (Fig. 21), the eWAT depot is more likely to develop 
fibrosis in vivo (290). To test if eWAT undergoes increased ECM deposition with 
fibrotic stimulus, eWAT and iWAT explants were isolated and then cultured with 
media changes on day 0, day 2, and day 4 in the presence or absence of TGFβ. 
Collagen accumulation was analyzed by picrosirius red staining and imaging with 
polarized light. Interestingly, TGFβ treatment had differential effects depending 
on WAT depot. Consistent with previous observations, the iWAT had increased 
perivascular and septa collagen deposition (Fig. 22). Increased collagen  
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Figure 21 – Inguinal adipose tissue explants exhibit increased extracellular 
matrix deposition with rACLP and TGFβ treatment. 
Inguinal adipose tissue explants were isolated from 12-week old C57BL6/J male 
mice were cultured in suspension with 10% FBS DMEM and 10 µg/ml insulin in 
the presence or absence of 3.75 µg/ml rACLP or 200 pM TGFβ for 10 days with 
media changes every 2 days. Inguinal adipose tissue explants isolated on days 0 
and 10 were stained with picrosirius red and then imaged using brightfield and 
polarized light. Closed arrows indicate perivascular ECM. Open arrows indicate 
septa. 
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Figure 22 – Inguinal adipose tissue explants exhibit increased extracellular 
matrix deposition with TGFβ treatment while epididymal adipose tissue 
explants do not.  
Epididymal adipose tissue explants (top panels) and inguinal adipose tissue 
explants (bottom panels) were isolated from 12-week old C57BL6/J male mice 
were cultured in suspension with 10% FBS DMEM and 10 µg/ml insulin in the 
presence of absence of 200 pM TGFβ for 4 days with a media change every 2 
days. White adipose tissue explants isolated on days 0, 2 and 4, were stained 
with picrosirius red and then imaged using brightfield and polarized light. Arrows 
show ECM accumulation.  
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deposition was not observed in eWAT (Fig. 22). These data demonstrate that 
iWAT has increased ability to deposit collagen in response to fibrotic stimuli 
compared to eWAT, however pericellular collagen deposition is not observed. 
Interestingly, these observations revealed that iWAT undergoes collagen 
deposition following TGFβ treatment while this is not observed in the eWAT (Fig. 
22). This observation is in contrast to in vivo studies that have demonstrated the 
opposite to occur, where eWAT undergoes fibrotic remodeling and iWAT does 
not with diet induced obesity (122, 132). Given this discrepancy, this suggests 
each WAT depot may respond differently to fibrotic stimuli. To test this, a kinetic 
study was performed. eWAT and iWAT were cultured under explant culture 
conditions for 4 days in the presence or absence of fibrotic stimuli, TGFβ. Total 
explants were harvested every 2 days and protein expression was analyzed. 
iWAT explants did not increase protein expression of ACLP over time or with 
TGFβ treatment, while eWAT explants had higher baseline ACLP protein 
expression that was rapidly decreased after 2 days of explant culture (Fig. 23). 
αSMA protein expression in iWAT remained near baseline levels with TGFβ and 
increased on day 4, however αSMA expression decreased without TGFβ 
treatment (Fig. 23). In eWAT, αSMA protein expression was higher at baseline 
and fluctuated in expression regardless of TGFβ treatment (Fig. 23). Perilipin 
protein expression in both depots decreased after day 0 and was not responsive 
to TGFβ treatment (Fig. 23). Adiponectin protein expression was unchanged in 
the eWAT, regardless of treatment (Fig. 23). Adiponectin increased in untreated  
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Figure 23 – The inguinal adipose depot responds to TGFβ treatment 
Inguinal adipose tissue explants and epididymal adipose tissue explants were 
isolated from 12-week old C57BL6/J male mice were cultured in suspension with 
10% FBS DMEM and 10 µg/ml insulin in the presence of absence of 200 pM 
TGFβ for 4 days with a media change every 2 days. Total tissue isolates were 
harvested on days 0, 2 and 4 and analyzed by SDS-PAGE and Western blot with 
antibodies against ACLP, αSMA, adiponectin, perilipin and CypA. This is figure is 
representative of 2 experiments.  
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iWAT explants but did not increase with TGFβ treatment (Fig. 23). Collectively 
these preliminary data demonstrate that while iWAT undergoes ECM 
accumulation with fibrotic stimuli (Fig. 22), Western blot analysis demonstrates 
the iWAT is responsive to TGFβ while the eWAT was not. Future studies will 
need to address individual WAT cell populations to observe response to fibrotic 
stimuli. 
ACLP-null cells deposit an extracellular matrix that does not enhance 
myofibroblast differentiation 
Several studies have demonstrated the impact of ECM structural 
properties and composition on adipogenesis and WAT function (103, 125, 291). 
ACLP is inhibitory to adipogenesis in vitro (Fig. 3B) and localizes with pericellular 
ECM deposition following diet induced eWAT fibrosis (Fig. 5B). While it is unclear 
the impact ACLP has on collagen structure and ECM remodeling, human 
mutations in AEBP1 have been demonstrated to be causative of connective 
tissue disorders (237, 238) and others have observed an anti-adipogenic activity 
for ACLP in a collagen rich environment (268). This suggests that ECM 
generated by cells expressing ACLP may promote fibrosis and be anti-
adipogenic. Utilizing a model of cell-derived matrix (121), wild type and ACLP-
null confluent MEFs were cultured for 10 days in the presence of ascorbic acid to 
promote ECM secretion (292, 293) and the presence or absence of TGFβ to 
promote fibrotic ECM accumulation (294, 295) (Fig. 24A). After 10 days, the MEF  
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Figure 24 – TGFβ treated ACLP-null MEF derived ECM modulates 
myofibroblast stromal-vascular cell differentiation  
A. A scheme of ECM generation, isolation and myofibroblast differentiation. 
Confluent wild type (wt) and ACLP-null mouse embryonic fibroblasts were given 
media with 50 µg/ml ascorbic acid with or without 200 pM TGFβ every 2 days for 
10 days. On day 10, mouse embryonic fibroblasts were removed and the ECM 
was retained. Freshly isolated epididymal adipose tissue stromal-vascular cells 
were plated on the isolated extracellular matrix for 4 days in 10% FBS DMEM 
with media changes every 2 days. B. Protein was harvested 4 days after plating 
and analyzed by SDS-PAGE and Western blot with antibodies against ACLP, 
Col1, αSMA and CypA. 
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ECM were decellularized with an NH4OH ECM isolation buffer and subsequent 
EDTA washes and the ECM was retained (266) (Fig. 24A). The isolated ECMs 
were used as surface substrates to promote myofibroblast differentiation and 
inhibit adipogenesis (Fig. 24A). 
To determine the ECM ability to enhance myofibroblast differentiation, 
freshly isolated eWAT SVF cells were cultured in duplicate on the ECM for 4 
days. Previous studies have demonstrated that myofibroblast differentiation 
occurs 4 days of culturing on tissue culture plastic (250). On day 4, SVF were 
harvested and analyzed for myofibroblast protein expression. In the absence of 
TGFβ, the ECM did not promote myofibroblast differentiation regardless of ACLP 
expression status, indicated by ACLP, collagen and αSMA protein expression 
(Fig. 24B). Notably the SVF cell response to non-TGFβ ECM was highly variable. 
Interestingly, ECM secreted in the presence of TGFβ did effect myofibroblast 
differentiation depending on ACLP expression (Fig. 24B). SVF cells on TGFβ 
treated ACLP-null ECM had decreased myofibroblast protein expression 
compared to TGFβ treated wild type ECM, as indicated by decreased ACLP, 
collagen and αSMA protein expression (Fig. 24B). Notably, these results are 
preliminary (n = 2) and there was substantial variability. Together these data 
suggest that TGFβ stimulated ECM secretion is altered in ACLP-null MEF. This 
altered ECM may decrease myofibroblast differentiation. 
To determine if these cell derived ECM inhibit adipogenesis, freshly 
isolated eWAT SVF were cultured in duplicate on the ECM for 9 days (Fig. 25A).  
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Figure 25 –ACLP-null MEF derived ECM has no effect on adipogenesis. 
A. A scheme of ECM generation, isolation and adipogenesis. Confluent wild type 
(wt) and ACLP-null mouse embryonic fibroblasts were given media with 50 µg/ml 
ascorbic acid with or without 200 pM TGFβ every 2 days for 10 days. On day 10, 
mouse embryonic fibroblasts were removed and the extracellular matrix was 
retained. Freshly isolated epididymal adipose tissue stromal-vascular cells were 
plated on the isolated extracellular matrix for 9 days in 10% FBS DMEM, 
adipogenesis was induced the day after plating. B. Protein was harvested 8 days 
following adipogenic induction and analyzed by SDS-PAGE and Western blot 
with antibodies against adiponectin, perilipin and CypA.  
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eWAT SVF were induced to undergo adipogenesis with DMII the day after plating 
(Fig. 25A). On day 8, SVF were harvested and analyzed for adiponectin and 
perilipin expression as markers of their differentiation status. Adipogenesis was 
similar, regardless of ACLP expression status or TGFβ treatment of ECM, as 
indicated by equal protein levels of adiponectin and perilipin (Fig. 25B). These 
results suggest that ACLP expression status in cells does not alter the 
adipogenic potential of the ECM. Notably, these results are preliminary (n = 2) 
and additional studies are needed. Furthermore, immunofluorescence analysis of 
ACLP in the MEF derived ECM was inconclusive (not shown).  
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CHAPTER VII – DISCUSSION 
The studies presented in this thesis demonstrate ACLP regulates adipose 
progenitor differentiation by repressing adipogenesis and enhancing 
myofibroblast differentiation. This work demonstrates that ACLP expression is 
dramatically decreased during adipogenesis of mouse and human adipose 
progenitors and was not primarily expressed in mature adipocytes. Previous 
studies have demonstrated that ACLP is a positive mediator of fibroblast to 
myofibroblast transition that is in part mediated through the TGFβR (250). These 
studies have further established that ACLP signaling is dependent on TGFβR 
activity. Using a mouse model of obesity induced WAT fibrosis, ACLP expression 
was localized to the pericellular ECM rich regions in fibrotic eWAT. Additionally, a 
significant source of ACLP expression in fibrotic eWAT is non-immune SVF cells. 
Furthermore, these studies also demonstrate that multiple SVF cells can undergo 
adipogenesis and myofibroblast differentiation. In summary, ACLP activates a 
pro-fibrotic signaling axis and is derived from non-immune cell types, 
representing a potential target to ameliorate WAT fibrosis. 
ACLP and adipogenesis 
ACLP expression is inversely correlated with adipogenesis, where 
expression is rapidly down-regulated with adipogenic induction in both mouse 
(Fig. 2B) and human (Fig. 8B,C) adipose progenitors. Furthermore, ACLP is not 
primarily expressed by differentiated adipocytes (Fig. 2B). This relationship of 
ACLP expression and adipogenesis is consistent with the work of others in 
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multiple adipose progenitor cell lines (230, 252-254). These studies have 
demonstrated that ACLP is an extracellular negative regulator of adipogenesis 
(Fig. 3B). Interestingly, adipose progenitors can express ACLP but remain 
adipogenic. Together this suggests that adipose progenitors can express but do 
not establish active extracellular ACLP signaling. For instance, secretion of ACLP 
in adipose progenitors may be low and cells may not establish an autocrine-
signaling loop. To test this, eWAT SVF cells from Cre-Aebp1flx/flx mice were 
isolated and treated with tamoxifen to induce Aebp1 recombination (Fig. 10A). 
mRNA was analyzed following Aebp1 knockout (Fig. 10A,B). Aebp1 expression 
was significantly reduced (51% reduction in mRNA expression), however multiple 
adipogenic and myofibroblast mRNA markers remained unaffected (Fig. 10B). 
This study suggests that loss of Aebp1 expression was insufficient in mediating 
myofibroblast or adipogenic differentiation. This is in contrast to previous work 
which demonstrated that knockdown of ACLP (68% reduction in protein 
expression) in differentiating lung fibroblasts abrogated myofibroblast 
differentiation (250). This may be due to numerous technical issues, where 
Aebp1 knockout was significant (51% reduction of mRNA expression) but 
insufficient in eliminating function (Fig. 10B). Additionally, this may be due to 
slight differences in the experimental procedures, where these experiments were 
cultured on tissue culture plastic for a longer period. The increased time on tissue 
culture plastic may have resulted in sufficient myofibroblast differentiation and the 
effect of ACLP knockdown was less apparent after multiple days of culturing. 
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Alternatively this may be related to intrinsic differences between lung fibroblasts 
and eWAT SVF. For instance, lung fibrosis is associated with an increase in 
αSMA+ myofibroblasts (226) while the studies presented here suggest that 
αSMA+ may not be a marker of myofibroblasts in WAT fibrosis (Fig. 5C).  
Interestingly, overexpression of ACLP has resulted in conflicting reports. 
One group has reported ACLP overexpression represses adipogenesis (232) 
while another group has demonstrated it had limited effect (254), however these 
were reported in different adipose progenitor lines. It will be important to 
delineate ACLP expression and secretion to understand its function. Collectively 
these studies suggest ACLP is repressive to adipogenesis, but adipose 
progenitors require additional inputs to establish a negative autocrine loop. The 
studies presented here demonstrate a mechanism for ACLP as an extracellular 
negative mediator of adipogenesis that signals through the TGFβR (Fig. 4B). 
Intracellular mediators 
While the exact mechanism of inhibiting adipogenesis was not defined, 
ACLP could be acting through numerous signaling pathways downstream of 
TGFβR. Adipogenesis is dependent on cell shape which is, in part, influenced by 
the actin cytoskeleton (80). Specifically, the ROCK mediated MRTFA-SRF 
transcriptional cascade is demonstrated to repress adipogenesis (87, 88). ACLP 
signaling enhancement of αSMA expression is partly dependent on ROCK 
activity (Fig. 11B). This is consistent with a previous report that demonstrated 
that ACLP mediates collagen expression independent of MRTFA (250). Together 
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this suggests ACLP signaling is partly mediated via a TGFβR-ROCK signaling 
axis, but other TGFβR mediators are more influential on the anti-adipogenic 
activity of ACLP. This is most likely mediated via the TGFβ-Smad2/3 signaling 
pathway. TGFβR-Smad2/3 activation is demonstrated to inhibit adipogenesis as 
active Smad3 complexes with C/EBPβ and inhibits transactivation of early 
adipogenic genes, including C/EBPα and PPARγ (73). The studies presented 
here demonstrate that ACLP inhibits upregulation of PPARγ (Fig. 3B), supporting 
that ACLP inhibits early C/EBP-activity. Previous studies have demonstrated that 
ACLP activates TGFβR-Smad2/3 signaling (250). It is likely that ACLP activates 
the TGFβR, resulting in ROCK and Smad2/3 activation. ROCK activation results 
in MRTFA-SRF mediated activation of αSMA and inactivation of PPARγ activity 
(87, 296). Smad2/3 activation results in expression of αSMA and collagen and 
inhibition of C/EBPβ activity.  
Furthermore, previous studies have demonstrated that ACLP can activate 
Smad1/5/9 activation via the TGFβR (250). Smad1 activation is demonstrated to 
enhance myofibroblast differentiation, independent of Smad2/3 activation (297, 
298). Certainly TGFβR-Smad1 activation could serve as a potential pathway for 
ACLP mediated myofibroblast differentiation. Interestingly, Smad1/5/9 activation 
is demonstrated to be pro-adipogenic with BMP signaling (69, 70). This might 
give insight into the function of ACLP in a non-fibrotic context. For instance, in 
non-stimulated adipose progenitors, ACLP may function by activating both 
Smad2/3 and Smad1/5/9 signaling pathways, either by promoting intracellular 
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cross-talk of the pathways or through activation of both TGFβR and BMP 
receptors, thereby maintaining the cells in a progenitor state. In the context of 
fibrosis, there might be a shift away from pro-adipogenic Smad1/5/9 and towards 
pro-myofibroblast Smad2/3 signaling. For instance, obesity is strongly associated 
with increased secretion of the inflammatory cytokine, interleukin-6 (IL6), derived 
from WAT (299, 300). IL6 signaling is demonstrated to stabilize the TGFβR and 
subsequently enhance its signaling (301). Given the link between WAT 
inflammation and fibrosis, this may serve as mechanism to shift away from 
adipogenic signaling. 
How ACLP activates TGFβR dependent signaling pathways is unknown. 
Previous studies have demonstrated that ACLP activates the TGFβR via the N-
terminal domain (302). The ACLP N-terminal domain consists of a region rich in 
lysines, prolines and glutamic acids that is predicted to form 4-Tsp like repeats 
(unpublished). Tsp can activate TGFβR signaling indirectly by activating latent-
TGFβ into the active form (166). While it is possible that ACLP can activate latent 
TGFβ via the N-terminal domain, previous studies have demonstrated that ACLP 
can activate Smad2/3 with similar kinetics to active TGFβ (250). This suggests 
that ACLP is a direct ligand to TGFβR.  
There are numerous other signaling pathways that are activated 
downstream of TGFβR as well as independent of TGFβR. Recently ACLP was 
demonstrated promote hepatic stellate cell to myofibroblast differentiation via 
Wnt signaling pathways (303). Wnt signaling activates β-catenin, which is 
  99 
demonstrated to be a mediator of fibrosis (303-305) and inhibitor of adipogenesis 
(306-308). ACLP functioned as a Wnt ligand by activating Wnt signaling 
receptors, frizzled (303). It is possible that ACLP inhibits adipogenesis through 
Wnt signaling pathways, however the results presented here demonstrate a 
dependence on TGFβR activity (Fig. 4B). This difference in Wnt and TGFβR 
signaling could be attributed to intrinsic differences between tissues and context. 
It is likely that ACLP activates ROCK-MRTFA and Smad2/3 via the TGFβR to 
enhance myofibroblast differentiation and repress adipogenesis (Fig. 26) 
however other pathways are likely involved. 
Extracellular matrix signaling 
Several studies have demonstrated the impact of ECM structural 
properties and composition on adipogenesis and WAT function (103, 125, 291). 
The studies presented here demonstrate that ACLP is inhibitory to adipogenesis 
in vitro (Fig. 3B,C, 8E,F) and localizes with peri-cellular ECM deposition with 
eWAT fibrosis (Fig. 5B). ACLP is a member of a class of proteins with an 
enzymatically inactive carboxypeptidase, which includes CPX1 and CPX2 (225, 
239, 240). In contrast to the function of ACLP, CPX1 expression is positively 
correlated with adipogenesis (309). Furthermore, CPX1 knockdown impairs 
adipogenesis and results in a reduction of ECM associated proteins (309). While, 
ACLP and CPX1 share a structurally similar enzymatically inactive 
carboxypeptidase and discoidin-like domains, they appear to have opposing  
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Figure 26 – ACLP mediated enhancement of myofibroblast differentiation 
and repression of adipogenesis model 
ACLP activates the TGFβR which activates downstream effectors, ROCK and 
Smad2/3. ROCK results in MRTFA activation and translocation to the nucleus, 
resulting in 1. Inhibition of PPARγ activity and 2. Activation of SRF and 
transcription of αSMA. Activated Smad2/3 results in 1. Association and inhibition 
of C/EBPβ transcriptional activity and 2. Translocation to the nucleus and 
activation of αSMA and Col1 gene expression.  
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effects on adipogenesis and ECM expression. This could be attributed to 
structural differences in the N-terminal domain. The ACLP N-terminal domain 
consists of a region rich in lysines, prolines and glutamic acids that is predicted to 
form 4-Tsp like repeats. This N-terminal region is substantially shorter in CPX1 
(225). While it is unclear the impact ACLP has on collagen structure and ECM 
remodeling, human mutations in AEBP1 have been recently shown to be 
causative of connective tissue disorders (237, 238). These patients presented 
with abnormal ECM structure. Consistent with a collagen associated function for 
ACLP, Gusinjac and colleagues observed an anti-adipogenic activity for ACLP in 
a collagen rich environment (268). Other studies using proteomics revealed 
ACLP is increased with fibrotic remodeling in a model of ischemia (249) and 
abdominal aortic aneurysm (248) which has lead to its recent designation as a 
core ECM protein (251).  
Previous studies have demonstrated that ACLP, specifically the collagen 
binding discoidin-like domain, rescues gel contraction in ACLP-null fibroblasts 
(226). This study suggests that the discoidin-like domain enhances cell-ECM 
interactions, potentially via integrin-FAK activation. The studies presented here 
do not conclusively demonstrate that ACLP signals via cell-ECM pathways. For 
instance, chemical inhibition of FAK with ACLP treatment did not rescue 
adipogenesis (Fig. 14B). Additionally, ACLP enhances myofibroblast 
differentiation, which is partially dependent of FAK activity (Fig. 12B) however 
this was not true on soft rigid substrates (Fig. 13B). Furthermore, FAK inhibition 
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independently repressed myofibroblast differentiation (Fig. 12B) and enhanced 
adipogenesis (Fig. 14B). A primary reason why FAK inhibition assays performed 
on tissue culture plastic were inconclusive may be due to the rigidity of tissue 
culture plastic. Tissue culture plastic is more rigid than most tissues by multiple 
orders of magnitude (310). Additionally, increased rigidity strongly enhances 
ROCK signaling and downstream effectors, including MRTFA-SRF (311). 
Inhibiting FAK signaling may not be sufficient to overcome plastic mediated 
ROCK activation in conjunction with ACLP mediated TGFβR activation. When 
cells were cultured on less rigid collagen surfaces any dependence on FAK 
activity was diminished. Collectively this suggests that FAK activity is sensitive to 
surface rigidity and tissue culture plastic is not an appropriate surface for FAK 
analysis activity. Myofibroblast differentiation was independent of FAK activity on 
4 kPa surface and on a 25 kPa surface (Fig. 13B). These studies suggest ACLP 
signaling is independent of FAK activity to repress adipogenesis or enhance 
myofibroblast differentiation. In addition to collagen binding, discoidin domains in 
other proteins are demonstrated to bind phospholipids in cell membranes (312). 
For instance, coagulation factors V and VIII mediate cell-cell contact via 
phospholipid membrane bound discoidin domains (313). Previous reports 
demonstrate that the discoidin-like domain enhances cell-ECM interactions in 
ACLP-null fibroblasts (226), this might be mediated independently of FAK. The 
discoidin-like domain might be enhancing cell-ECM interactions at the expense of 
cell-cell interactions. For instance, ACLP could be functioning similar to SPARC. 
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SPARC, an ECM associated glycoprotein, enhances cell-ECM interactions at the 
expense of cell-cell interactions (115). Similar to ACLP, SPARC is associated 
with fibrosis and is enriched in obese WAT (114, 314). It is possible that 
discoidin-like domain indirectly enhances integrin-FAK activity by increasing cell-
ECM interaction, however this requires an alternative experimental design than 
those performed here. 
Additionally, ACLP may interact with the ECM similar to the ECM bound 
form of latent-TGFβ (164). TGFβ is often sequestered in the ECM as a latent 
protein (164). TGFβ can be activated from the ECM through enzymatic cleavage 
via MMPs (165) or dissociation by Tsp (166), integrins (168, 169) and through 
myofibroblast contraction (110). ACLP may also bind the ECM via the discoidin-
like domain and through other domains it can activate signaling pathways, like 
TGFβR. The N-terminal domain of ACLP is specifically able to activate the 
TGFβR-Smad2/3 signaling pathway (302). Similar to ECM bound TGFβ, ACLP 
may be enzymatically or mechanically cleaved following an injury resulting in 
liberation of the N-terminal region and retention of the discoidin-like containing 
domain on the ECM. The liberated N-terminal domain subsequently activates 
TGFβR signaling. Western blot analysis of tissue or primary mouse cells 
consistently demonstrated multiple bands associated with ACLP (Fig. 5C, 23, 
24B). The top band is the glycosylated form of ACLP and the band immediately 
below is the full length non-glycosylated ACLP (233). There are often two smaller 
bands observed and one possibility is that the could represent an enzymatically 
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processed ACLP. This suggests that ACLP may be processed and support an 
ECM bound latent-TGFβ signaling type model however more work is required to 
understand these smaller bands of ACLP. 
Differentiation studies were performed on isolated ECM generated by wild 
type and ACLP-null MEFs (Fig. 24A, 25A). MEFs were also treated with TGFβ to 
enhance fibrotic ECM deposition and remodeling (Fig. 24A, 25A). Adipogenesis 
was unaffected by the ECM (Fig. 25B). For myofibroblast differentiation studies, 
untreated ECM from both wild type and ACLP-null MEFs were inconclusive (Fig. 
24). Interestingly, addition of TGFβ to the MEFs altered the ECM, where the 
ECM generated by TGFβ treated ACLP-null MEFs resulted in a diminished 
myofibroblast differentiation (Fig. 24B). This difference in impacting myofibroblast 
differentiation but not adipogenesis is potentially due to the technical limitations 
of the experiment. The adipogenic induction is a powerful signal and most likely 
overcomes any effect of the ECM. In contrast, the ECM serves as the primary 
stimulus in the myofibroblast differentiation study. The myofibroblast 
differentiation study was performed simply by plating eWAT SVF cells on to the 
ECM in high serum, as previously reported (250). While the mechanism or 
changes to the ECM were not explored in these studies, it does demonstrate 
ACLP expression is important to TGFβ mediated ECM remodeling. 
Aebp1 and adipogenesis 
The gene name for ACLP is adipocyte enhancer binding protein 1 which is 
described as a different protein that is a negative mediator of adipogenesis (228, 
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230). Aebp1 is described as a mouse intracellular protein with protease and 
transcriptional regulatory activity that shared sequence homology with discoidin-
like like domain (227-230). Specifically, Aebp1 was described as a repressor of 
adipogenesis via repressive interactions with the adipocyte enhancer element 
upstream of the FABP4 promoter (230). Notably, subsequent studies failed to 
reproduce this transcriptional regulatory activity (229, 232). Furthermore, it is 
important to note that subsequent genomic analysis have revealed the original 
Aebp1 protein was the result of a cloning artifact and that Aebp1 is the C-
terminus region of full length ACLP (231, 232). Despite these revelations, Aebp1-
null mice reveal a function important to WAT function and inflammation. 
Importantly, these mice did not express the Aebp1 protein (228). For instance, 
Aebp1-null fibroblasts were less proliferative compared to wild type, however no 
mechanism was reported (228). The studies presented here and previous studies 
demonstrate that ACLP is a regulator of TGFβR activation (Fig. 4B) (250). 
TGFβR activity promotes fibroblast proliferation (315). It is likely that Aebp1-null 
fibroblasts were unable to activate TGFβR, resulting in decreased proliferation. 
Furthermore, Aebp1-null mice were demonstrated to have decreased adiposity 
and are resistant to diet induced obesity (228). The studies presented 
demonstrate that ACLP upregulation is correlated with diet induced obesity, 
specifically during WAT fibrosis (Fig. 5B,C). Additionally, it is important to 
recognize that adiposity between wild type and Aebp1-null mice differed starting 
at 10 weeks of age and older (228). Jiang et al. demonstrated that adipose 
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progenitors in adult mice, and not developing or neonatal mice, are of a smooth 
muscle origin (27). ACLP expression is strongly associated with smooth muscle 
cells (244, 247). Collectively, the reduced adiposity of Aebp1-null mice could be 
due to reduced proliferation or survival of smooth muscle cells, which in turns 
results in a diminished adipose progenitor pool in adult mice. The studies here 
suggest ACLP correlates with the observations in the Aebp1-null mice, however 
it is functionally different. These results support that ACLP is a negative regulator 
of adipogenesis, including inhibition of FABP4 expression (Fig. 3B), however this 
is mediated through the TGFβR, potentially via an autocrine signaling loop (Fig. 
4B) (250). 
ACLP in the context of WAT fibrosis 
WAT fibrosis is histologically described as ECM deposition surrounding 
individual adipocytes, termed as pericellular ECM deposition (102, 134). 
Immunofluorescence analysis of fibrotic eWAT demonstrates that ACLP 
becomes localized in regions consistent with pericellular ECM deposition (Fig. 
5A,B). Numerous studies have demonstrated that chronic obesity is associated 
with a immune cell expansion, via recruitment and proliferation of both resident 
and circulating immune cells (95, 98, 99). These immune cells surround and 
facilitate removal of dying and dead adipocytes, observed as a CLS (95, 98, 99). 
While the appearance of CLS is positively correlated with chronic obesity and is a 
marker of metabolic dysfunction (17), they are essential for adipocyte turnover 
during acute caloric excess and deficit (15). CLS also positively correlate with 
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pericellular ECM deposition with chronic obesity (17). Interestingly no studies 
have demonstrated that myofibroblasts, cells most likely responsible for 
pericellular ECM deposition, associate with CLS with chronic obesity. Divoux et 
al. observed an increase in αSMA expressing cells not associated with the 
vasculature but did not demonstrate association with pericellular ECM deposition 
(102). More recently, a report demonstrated mice with constitutively active 
PDGRα in WAT undergo increased fibrosis and there is an increase in 
perivascular cells associated with pericellular ECM deposition (123). These data 
demonstrate that ACLP expressing cells associate within regions resembling a 
CLS (Fig. 5B). Importantly, analysis of ACLP mRNA expression demonstrates 
that in fibrotic eWAT, the CD45-, or non-immune, cells are the primary source of 
ACLP expression (Fig. 6B). Furthermore, CD45- cells express the bulk of ECM 
proteins (Fig. 6B). Together, suggesting these ACLP expressing cells is an ECM 
producing cell that associates with CLS. 
Understanding the relationship between immune cell expansion and ACLP 
expression in non-immune cells could provide novel insights into the progression 
of WAT fibrosis. Vila et al. demonstrated that depletion of macrophages in 
chronically obese mice resulted in attenuation of WAT fibrosis (290). One 
possibility is that ACLP expression is a consequence of immune cell expansion. 
This concept has been demonstrated in experimentally induced lung fibrosis, 
where genetic ablation of ACLP protected against fibrosis with reduced αSMA+ 
myofibroblast expansion however immune cell expansion was observed (226). 
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Immune cells, namely macrophages, were demonstrated to secrete pro-
myofibroblast mediators, including members of TGFβ superfamily (119, 120). 
ACLP expression is enhanced with TGFβ signaling (249, 254). Together, these 
studies support that increased ACLP expression may be a consequence of 
immune cell expansion, potentially mediated via TGFβ secretion (Fig. 27). ACLP 
may play a role in fibrosis similar to connective tissue growth factor (CTGF), a 
secreted matrix associated cytokine, which is activated with TGFβ signaling 
(316). CTGF is demonstrated to promote the myofibroblast differentiation 
activities attributed to TGFβ signaling (317, 318). Recent phase II clinical trials 
investigating a monoclonal antibody against CTGF in patients with idiopathic 
pulmonary fibrosis have been successful and suggest that targeting downstream 
effectors of TGFβ is valid (319). Together these data support that ACLP is a 
potential therapeutic target that increases with fibrosis in eWAT as a 
consequence of inflammation. 
Defining the ECM source 
In numerous tissues, fibrosis is mediated by myofibroblast which is 
characterized in part by increased co-expression of ECM genes and αSMA (127). 
However myofibroblasts are a heterogeneous cell type and can vary widely 
tissue to tissue (136). Recent studies have highlighted a sub-population of 
PDGFRα+ perivascular adipose progenitors which contribute to myofibroblast 
expansion with chronic obesity (122). Marcelin et al. reported that PDGFRα+  
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Figure 27 – ACLP in the context of fibrosis model 
Inflammation increases TGFβ signaling in WAT resulting in increased ACLP 
expression and secretion in adipose progenitors. Increased ACLP signaling 
inhibits adipocyte hyperplasia by repressing adipogenesis and instead increases 
myofibroblast differentiation. WAT myofibroblasts secrete ACLP further 
repressing adipogenesis and promoting myofibroblast differentiation.  
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CD9low SVF cells decrease in number with chronic obesity along with an increase 
with PDGFRα+ CD9high SVF cells (122). Additionally, it was demonstrated this 
shift in CD9 expression correlated with adipogenic potential, where CD9low were 
adipogenic while CD9high were not (122). While these studies demonstrate a 
clear SVF sub-population that changes with chronic obesity, myofibroblasts and 
adipose progenitors can arise from multiple cell types. 
The studies presented here analyzed adherent fibroblastic SVF cells from 
αSMA-mCherry/Col1-GFPtpz male mice for adipogenic and myofibroblast 
differentiation. αSMA-/Col1+ SVF cells contributed to myofibroblast and 
adipocyte populations with equal capacity as αSMA-/Col1- SVF cells (Fig. 15, 
16). While PDGRα expression analysis was not performed, PDGRα+ (153) and 
αSMA-/Col1+ (Fig. 17) are both perivascular SVF cells suggesting that these 
may mark the same cell. Additionally Marcelin et al. reported that PDGFRα+ 
oWAT SVF cells derived from obese humans express both αSMA and ECM 
proteins, however there was no analysis if these cells co-expressed αSMA and 
ECM proteins (122). Interestingly, Western blot analysis of the HFD SVF 
demonstrates a substantial decrease of αSMA expression in total SVF with HFD 
(Fig. 5C). This observation in contrast to PDGFRα+ CD9high SVF cells which 
exhibit increased αSMA expression with obesity, however this was observed in 
C3H male mice (122). The loss of overall αSMA expression in SVF is potentially 
due to dedifferentiation of αSMA+ adipose vascular smooth muscle cells (VSMC) 
to an αSMA- ECM producing phenotype, which is well documented in settings of 
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vascular injury (320) and inflammation (321). Given the close correlation of WAT 
fibrosis with chronic inflammation, its conceivable that elevated inflammatory 
cytokines, such as tumor necrosis factor-α, repress αSMA transcription in VSMC 
(5, 322). However, the SVF of chow and HFD expressed comparable levels of 
additional VSMC markers, SM22, CRP2 and desmin, (Fig. 5). Furthermore, 
ACLP protein expression was higher in the HFD SVF compared to the chow SVF 
(Fig. 5C). While ACLP is normally expressed by αSMA+ expressing VSMC, 
following injury ACLP expressing VSMC proliferate but no longer express αSMA 
(247). Together this suggests dedifferentiation of VSMC may account for the 
overall decrease of αSMA in total SVF, however changes in VSMC markers may 
be differentially regulated. Alternatively, the loss of αSMA may not be related to 
the vasculature. For instance, in fibrotic eWAT there is a large expansion of cells 
(Fig. 5) which is likely due to immune cell expansion (323). This immune cell 
expansion results in potential dilution of αSMA+ myofibroblasts in the total SVF, 
thereby reducing the αSMA expression across the total SVF. Additionally, these 
studies demonstrate that SVF cells respond to fibrotic stimuli in vitro with 
differential increases in expression of αSMA and collagen I (Fig. 15, 20). This 
leads to the possibility where the ECM producing cell population in adipose 
tissue is not predominately αSMA+. While others have demonstrated an increase 
in αSMA in the SVF with obesity, these only represent the response of a SVF 
sub-population (102, 119, 122). While αSMA expression a defining marker for 
myofibroblasts, myofibroblast contractile stress fibers do not always contain 
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αSMA but are phenotypically similar (146). Collectively, this suggests that 
myofibroblast may not accurately represent the primary ECM producing cell in 
WAT fibrosis, rather the cell is an activated fibroblast. 
In non-WAT tissues, smooth muscle cells contribute to myofibroblast 
expansion during progression of fibrosis (159). αSMA is a marker of smooth 
muscle cells affiliated with larger blood vessels and arterioles (324). Lineage 
tracing studies using an indelible αSMA+ have demonstrated that adipose 
progenitors are derived from an αSMA+ vascular origin (24, 27). αSMA 
expressing SVF cells are not readily cultured, rather they are retained in intact 
vasculature, or SVP (24, 27). Culturing of SVP on tissue culture plastic resulted 
in rapid expansion of perivascular αSMA-/Col1+ cells, however there was no 
observed proliferation αSMA+ cells (Fig. 17). Furthermore, when SVP were 
cultured in a 3D collagen environment and induced to undergo adipogenesis, no 
adipogenesis observed (Fig. 18). This is contrast to reported SVP studies that 
demonstrate that cells of the SVP undergo adipogenesis in a floating culture (24). 
This inability to undergo adipogenesis may be attributed to the collagen gel 
embedding, which may slow the progression of adipogenesis as additional 
physiological activities, such as ECM remodeling may be required (77). 
Interestingly, TGFβ treatment disrupted the SVP integrity as observed by 
migration of αSMA+ and Col1+ cells into the collagen gel (Fig. 18). Additionally, 
TGFβ treatment resulted in the appearance of αSMA+/Col1+ SVF cells, however 
their origin remains unknown (Fig. 18). Collectively these studies suggest that 
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αSMA+ vascular cells give rise to adipose progenitors and may also contribute to 
myofibroblast expansion. SVP analysis demonstrated that αSMA+/Col1- SVF 
cells do not proliferate with standard culturing on plastic (Fig. 17), but can 
proliferate when treated with TGFβ (Fig. 18). This suggests that αSMA+/Col1- 
SVF cells are more resistant to myofibroblast differentiation than αSMA-/Col1+ 
perivascular cells. As discussed above, this may be in part due to 
dedifferentiation of αSMA+ cells into ECM producing αSMA- cells. These studies 
do demonstrate a rapid proliferation of αSMA-/Col1+ SVF cells, and it is certainly 
possible that αSMA+ cells are contributing to this proliferation (Fig. 17). 
In addition to adipose progenitors and smooth muscle cells, recent studies 
have suggested that adipocytes may be responsible for ECM deposition in the 
context of fibrosis. For instance, Marangoni et al. reported parallel loss of 
adipocytes and increase in fibrotic skin in an experimental model of scleroderma 
(124). Additionally, using lineage tracing myofibroblasts originated from 
adiponectin expressing cells, suggesting that adipocytes were capable of 
dedifferentiating from adipocytes to myofibroblasts, however this transition was 
not demonstrated (124). This is further complicated by the use of adiponectin for 
lineage tracing. While adiponectin is widely utilized as an adipocyte specific 
marker, reports have demonstrated that aortic VSMC do express adiponectin 
(325). The studies presented here demonstrate that the adipocyte fraction from 
fibrotic eWAT expresses ECM mRNA, including Col1α2, Col3α1, Col6α3, at 
similar levels to CD45- SVF (Fig. 6B). These observations cannot discount the 
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contribution of non-adipocytes attached to the buoyant adipocytes. For instance, 
there was a marked increase in presumably dead adipocytes associated CLS in 
fibrotic eWAT (Fig. 5B) (17), and these plin1 negative structures may retained in 
the buoyant fraction. However the adipocytes expressed very low levels of Aclp, 
CD45 and very high levels of adipocyte markers, plin1 and adipoq (Fig. 6), 
suggesting some myofibroblast and immune markers were not captured in the 
adipocyte fraction. Adipocytes could potentially contribute to ECM production 
directly or via adipocyte to myofibroblast transition (124). Adipocytes are highly 
secretory cells and function as a major endocrine organ that secretes systemic 
hormones, including adiponectin (326, 327). Therefore it is not unreasonable that 
adipocytes could also secrete ECM proteins. One possibility is via activation of 
MRTFA-SRF transcriptional activity. MRTFA-SRF transcriptional activity is a 
negative mediator of adipogenesis which is down-regulated with adipogenesis 
(87). Importantly, numerous reports have demonstrated that MRTFA-SRF is 
active in adipose progenitors (88, 281). It is possible that adipocytes can 
reactivate MRTFA-SRF signaling activity and subsequently enhance collagen 
transcription. 
Depot differences 
In mice, not all the WAT depots respond to chronic obesity by undergoing 
fibrosis (122, 132). The eWAT of male mice are more prone to undergo severe 
inflammation, hypoxia and fibrosis compared to the gonadal WAT of females and 
other WAT depots in mice (31, 122, 132). These data demonstrate the iWAT 
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undergoes increased ECM deposition following TGFβ treatment, while this was 
not observed in the eWAT (Fig. 22). The increased ECM deposition observed in 
the iWAT was predominately observed in the septa (Fig. 22), or ECM that 
physically compartmentalizes the WAT (102). This type of ECM deposition is not 
considered WAT fibrosis as it is correlated with an improved metabolic profile 
(133, 134). Pericellular ECM deposition is considered bona fide WAT fibrosis as 
it is correlated with metabolic dysfunction (17, 102, 122, 132). This increased 
response observed in the iWAT explant could be due to several factors. At the 
cellular level, the cellular composition varies between depots, where the iWAT is 
~75% non-adipocytes while the eWAT is ~50% non-adipocytes (328). 
Interestingly, eWAT SVF contains more PDGFRα adipose progenitors compared 
to iWAT SVF (26, 329), however iWAT PDGFRα adipose progenitors are more 
adipogenic (330, 331). Furthermore, eWAT expansion is more reliant on 
hyperplasia while iWAT expansion is reliant on hypertrophy (15, 332, 333). 
Together, this suggests that the iWAT SVF contains comparatively more non-
adipocyte cells, however a smaller number are tuned for adipogenesis. The 
remaining non-adipogenic cells could be important in the maintenance of ECM 
integrity of the iWAT. Supporting this, the ECM composition of the depot also 
varies. In rats, histological analysis demonstrates that iWAT adipocytes associate 
with more ECM proteins, including Col1 and fibronectin, compared to eWAT 
(334). These reports suggest possible explanations for increased ECM 
deposition following TGFβ treatment in the iWAT (Fig. 22). The higher basal 
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ECM and relatively increased number of SVF in iWAT suggest there are more 
cells associated with ECM deposition, and these cells may be activated with 
TGFβ in the explant system. One reason for the increased ECM of iWAT is that 
iWAT is associated with the surface of the skin and functions as a cushion 
against external stresses. ECM expression is increased in tissue following 
external mechanical stress, such as exercise (335), therefore it is possible that 
skin associated WAT have already adapted to express more ECM. 
Importantly, pericellular ECM deposition was not observed in the explant 
studies following TGFβ treatment (Fig. 22), suggesting that WAT fibrosis may 
require additional inputs. For instance, Vila et al. demonstrated that chemical 
depletion of macrophages or inactivation of toll-like receptor-4 abrogated WAT 
fibrosis (290), further suggesting inflammation is critical to progression of WAT 
fibrosis. While the studies presented here initiated fibrosis with TGFβ1, reports 
have demonstrated that other members of the TGFβ superfamily may play a 
significant role in myofibroblast differentiation (119). For instance, inhibin αB, a 
TGFβ superfamily member, was a more potent macrophage derived enhancer of 
myofibroblast differentiation in adipose progenitors compared to TGFβ1 (119). 
Non TGFβ mediators most likely play a significant role in WAT fibrosis. For 
instance, mice with constitutively activated PDGFRα develop WAT fibrosis 
independent of inflammation, suggesting that PDGFRα activity is important in 
WAT fibrosis progression (123). 
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Human white adipose tissue and ACLP 
Unlike mice, humans develop obesity induced WAT fibrosis across 
multiple WAT depots, including the sWAT and oWAT depots (17, 102). Similar to 
the eWAT in mice, the oWAT exhibits increased inflammation and adipocyte cell 
death, resulting in increased in CLS formation, with obesity (4, 95, 336). 
Furthermore, oWAT fibrosis is often associated with increased immune infiltration 
compared to sWAT fibrosis (102). Interestingly fibrosis in the oWAT depot is 
correlated with metabolic dysfunction (337). Data presented here demonstrate 
that both hASCs from oWAT and sWAT depot express ACLP, which is 
decreased with adipogenesis (Fig. 8B,C). Interestingly, ACLP expression 
recovered during adipogenesis in the oWAT hASCs as compared to sWAT 
hASCs (Fig. 8B,C). This is likely due to the decreased adipogenic potential of 
oWAT hASC compared to sWAT hASCs (337-339), where fewer oWAT cells 
underwent adipogenesis and these non-differentiated cells re-expressed ACLP. 
Currently no studies have explored if ACLP is higher expressed in oWAT hASCs. 
oWAT hASCs express and secrete increased amounts of ECM and inflammatory 
mediators and proteins (340, 341). The ECM proteins include collagens I & III, 
fibronectin and ECM associated proteins, MMPs, (340, 341) some of which have 
been demonstrated to correlate with ACLP (251). Given this, one possibility is 
that ACLP is expressed and secreted at a higher rate in oWAT hASC and may 
contribute to the limited adipogenic potential. Further studies demonstrated 
sWAT hASC underwent decreased adipogenesis with rACLP treatment, however 
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the reduction in adipogenesis and increase in myofibroblast markers varied 
among donors (Fig. 8E,F). This suggests that ACLP can promote myofibroblast 
differentiation in sWAT hASC, however the pro-adipogenic characteristic of 
sWAT hASC may resist ACLP activity. One possibility for this resistance is that 
sWAT hASC express higher amounts of TGFβR-3 compared to oWAT hASC 
(342). TGFβR-3 can negatively regulate the TGFβR-Smad2/3 signaling axis, as it 
can sequester TGFβ ligands thereby reducing their activity (343). Previous 
studies have demonstrated that ACLP acts via the TGFβR-Smad2/3 signaling 
cascade (250). Increased TGFβR-3 may be reducing the bioavailability of ACLP 
to TGFβR and this is a potential source of resistance of sWAT hASC against 
ACLP signaling. Further studies are warranted exploring analyzing ACLP 
regulation by TGFβR-3 and the relationship between ACLP signaling and oWAT 
hASC.  
These data demonstrate ACLP represses adipogenesis primarily via 
TGFβR activity (Fig. 4B) which is consistent with previous reports (250). 
Additionally, our laboratory previously demonstrated that ACLP can enhances 
myofibroblast through TGFβR dependent and independent mechanisms, which 
remains unknown (250). Recently it has been demonstrated that ACLP enhances 
hepatic stellate cell activation as a Wnt ligand (303). Other reports have 
demonstrated that oWAT hASC expressed increased amounts of Wnt receptors, 
named Frizzled, compared to sWAT hASC (344). Furthermore, it was 
demonstrated that Wnt signaling exacerbated WAT inflammation, however there 
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was no connection to WAT fibrosis (344). While these reports demonstrate 
different Frizzled isoforms are associated for their pathology, there is cross-
reactivity for Wnt ligands with different Frizzled isoforms (345). It is certainly 
feasible that ACLP is a Wnt ligand, but the decreased amount of Frizzled 
receptors in sWAT hASC results in a blunted cellular response to ACLP. 
Conclusions 
These studies demonstrated that ACLP enhances the differentiation of 
mouse and human adipose progenitors to a myofibroblast phenotype at the 
expense of adipogenic differentiation (Fig. 27). Importantly, ACLP is derived from 
non-adipocytes and non-immune cells, and is localized with peri-cellular ECM 
deposition in fibrotic WAT. ACLP activity may represent a novel therapeutic 
target that is independent of inflammation in ameliorating WAT fibrosis.  
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